STOCK TITAN

Estrella Immunopharma: $92.5K cash, going-concern doubt

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Estrella Immunopharma, Inc. (ESLA) reported a $7,382,080 net loss for the three months ended September 30, 2026, versus $4,801,149 a year earlier; nine-month net loss was $11,980,483 versus $12,450,338. Net cash used in operations for the nine months was $8,695,960, compared with $1,608,192. At September 30, cash and cash equivalents were $92,458 against $15,642,730 in current liabilities, including approximately $15.1 million in accrued related-party dosing obligations. Management determined there is substantial doubt about the company’s ability to continue as a going concern and said financing plans were not probable of being effectively implemented.

Sixteen patients had been dosed in the STARLIGHT-1 EB103 trial by September 30 (nine Phase I and seven Phase II); two additional patients were dosed in October, and the company recorded $2.75 million in additional milestones. Nasdaq gave the company until February 16, 2027 to regain compliance with its $1.00 minimum bid-price rule and until March 1, 2027 to address a market value below $35.0 million; the September 1 notice said it had no immediate effect on listing or trading. Effective October 25, Cynthia Pussinen became CEO, Chairperson of the Board and a Class I director; Cheng Liu, Ph.D., became Chief Scientific Officer and remained President and a director.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 3 points

How the balance works

Positive

  • None.

Negative

  • Major pointGoing-concern doubt: $92,458 cash against $15,642,730 in current liabilities.
  • Moderate pointThird-quarter net loss widened to $7,382,080 from $4,801,149.
  • Moderate pointNine-month operating cash used rose to $8,695,960 from $1,608,192.

Filing Explained

At September 30, 2026, the 7,594,935 offering warrants were unexercised, so their potential share issuance and related dilution remained conditional.

The January 2026 offering was completed, but its 7,594,935 common-stock warrants remained unexercised at September 30, 2026; exercising them at $1.39 per share would add shares and reduce existing holders’ percentage ownership.

By contrast, all 1,000,000 pre-funded warrants had been exercised and the underlying shares issued during the nine months ended September 30; none remained unexercised at quarter end.

On November 2, 2026, Cynthia Pussinen received an option to purchase 1,000,000 shares at $0.4263 per share; 25% vests on October 25, 2027, with the remainder vesting in 36 monthly installments, subject to continued service. The grant is an option, not an issuance of common stock; any resulting shares depend on vesting and exercise and would dilute existing holders’ percentage ownership if issued.

The STARLIGHT-1 services agreement sets $33 million in milestone fees if all milestones are achieved, based on 20 patients and one site, with $0.5 million for second-site activation and pass-through costs additional. That total is not the amount unpaid at quarter end: the company reported $10.9 million paid and $15.1 million accrued for outstanding dosing milestones.

Cash and cash equivalents $92,458 As of September 30, 2026
Current liabilities $15,642,730 As of September 30, 2026
Three-month net loss ($7,382,080) Three months ended September 30, 2026; ($4,801,149) in 2025
Nine-month net loss ($11,980,483) Nine months ended September 30, 2026; ($12,450,338) in 2025
Net cash used in operating activities $8,695,960 Nine months ended September 30, 2026; $1,608,192 in 2025
STARLIGHT-1 patients dosed 16 patients As of September 30, 2026: nine in Phase I and seven in Phase II
Minimum bid price $1.00 per share Nasdaq deficiency notice; compliance period through February 16, 2027
Market value of listed securities minimum $35.0 million Nasdaq deficiency notice; compliance period through March 1, 2027
going concern financial
"substantial doubt about its ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
registered direct offering financial
"consummated a registered direct offering and a concurrent private placement"
A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.
Pre-Funded Warrants financial
"issued Pre-Funded Warrants to purchase 1,000,000 shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
True-Up Shares financial
"issuance of the True-Up Shares"
Investigational New Drug (IND) regulatory
"IND application for EB103"
An investigational new drug (IND) is a drug or biologic that is being tested but has not yet been approved for general use; it is the application and formal status that allows a company to begin human clinical trials under regulator oversight. Investors care because an IND marks the transition from lab work to human testing — like getting a permit to run real-world experiments — which creates important milestones, costs, timelines and regulatory risk that drive a development-stage company's value.
Phase I/II clinical trial medical
"Phase I/II clinical trial of EB103"
A Phase I/II clinical trial is a combined early-stage study that first checks whether a new drug or treatment is safe for people and then looks for initial signs that it works. Think of it as a safety inspection followed by a short test drive: researchers monitor side effects, appropriate dosing, and early effectiveness. For investors, results from these trials matter because they reduce scientific uncertainty and can significantly change a development program’s value and the likelihood of later regulatory approval.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did ESLA identify substantial doubt about continuing as a going concern?

Management cited $92,458 of cash and cash equivalents against $15,642,730 of current liabilities as of September 30, 2026, plus $8,695,960 of operating cash use in the first nine months. It said additional financing had not been secured and financing plans were not probable of being effectively implemented.

What are ESLA's Nasdaq compliance deadlines?

The minimum-bid-price deficiency has a compliance period through February 16, 2027, after the stock closed below $1.00 for 30 consecutive business days. A separate market-value deficiency has a compliance period through March 1, 2027, after listed securities were below $35.0 million for 30 consecutive business days. The September 1 notice said it had no immediate effect on listing or trading.

What compensation terms did ESLA set for new CEO Cynthia Pussinen?

Her agreement sets annual base salary at $250,000, subject to automatic increases to $400,000, $450,000 and $525,000 when cumulative qualifying funding received after October 25, 2026 first exceeds $35.0 million, $55.0 million and $75.0 million, respectively. It also provides a target 2026 annual cash bonus of 60% of base salary. An option for 1,000,000 shares was granted November 2, 2026, at $0.4263 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
1 1 http://fasb.org/srt/2026#ChiefExecutiveOfficerMember P15D 1 1 0001844417 false Q3 --12-31 0001844417 2026-07-01 2026-09-30 0001844417 us-gaap:SubsequentEventMember 2026-10-01 2026-10-31 0001844417 srt:ScenarioForecastMember 2027-10-25 2027-10-25 0001844417 us-gaap:SubsequentEventMember 2026-11-02 2026-11-02 0001844417 2026-09-30 0001844417 srt:ScenarioForecastMember 2026-12-31 2026-12-31 0001844417 esla:AnnualIncrementThreeMember 2026-10-25 2026-10-25 0001844417 esla:AnnualIncrementTwoMember 2026-10-25 2026-10-25 0001844417 esla:AnnualIncrementOneMember 2026-10-25 2026-10-25 0001844417 2026-10-25 2026-10-25 0001844417 us-gaap:SubsequentEventMember 2026-10-01 0001844417 2026-01-01 2026-09-30 0001844417 2025-01-01 2025-09-30 0001844417 2025-07-01 2025-09-30 0001844417 srt:ScenarioForecastMember 2026-07-01 2026-12-31 0001844417 2026-01-01 2026-06-30 0001844417 2025-07-01 2025-12-31 0001844417 2025-01-01 2025-06-30 0001844417 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-09-30 0001844417 us-gaap:EmployeeStockOptionMember 2026-09-30 0001844417 us-gaap:EmployeeStockOptionMember 2025-12-31 0001844417 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-12-31 0001844417 2024-10-30 2024-10-30 0001844417 srt:MaximumMember 2024-10-30 2024-10-30 0001844417 srt:MinimumMember 2024-10-30 2024-10-30 0001844417 2024-10-30 0001844417 2025-01-01 2025-12-31 0001844417 esla:TwoThousandAndTwentyThreePlanMember 2025-01-01 2025-12-31 0001844417 esla:TwoThousandAndTwentyThreePlanMember 2026-01-01 2026-09-30 0001844417 esla:GeneralAndAdministrativeExpensesMember 2025-01-01 2025-09-30 0001844417 esla:GeneralAndAdministrativeExpensesMember 2026-01-01 2026-09-30 0001844417 esla:GeneralAndAdministrativeExpensesMember 2025-07-01 2025-09-30 0001844417 esla:GeneralAndAdministrativeExpensesMember 2026-07-01 2026-09-30 0001844417 esla:ResearchAndDevelopmentExpensesMember 2025-01-01 2025-09-30 0001844417 esla:ResearchAndDevelopmentExpensesMember 2026-01-01 2026-09-30 0001844417 esla:ResearchAndDevelopmentExpensesMember 2025-07-01 2025-09-30 0001844417 esla:ResearchAndDevelopmentExpensesMember 2026-07-01 2026-09-30 0001844417 2026-08-01 2026-08-31 0001844417 esla:TwoThousandAndTwentyThreePlanMember 2026-09-30 0001844417 esla:TwoThousandAndTwentyThreeOmnibusIncentivePlanMember 2026-01-01 0001844417 esla:TwoThousandAndTwentyThreeOmnibusIncentivePlanMember 2025-01-01 0001844417 esla:TwoThousandAndTwentyThreeOmnibusIncentivePlanMember 2024-01-01 0001844417 esla:TwoThousandAndTwentyThreeOmnibusIncentivePlanMember 2023-07-31 0001844417 esla:StockRepurchaseProgramMember 2026-09-30 0001844417 esla:StockRepurchaseProgramMember 2025-12-31 0001844417 esla:StockRepurchaseProgramMember 2025-01-01 2025-12-31 0001844417 esla:StockRepurchaseProgramMember 2026-01-01 2026-09-30 0001844417 esla:StockRepurchaseProgramMember 2025-09-30 0001844417 esla:StockRepurchaseProgramMember 2025-01-01 2025-09-30 0001844417 2024-01-30 2024-01-30 0001844417 us-gaap:WarrantMember 2026-01-01 2026-09-30 0001844417 us-gaap:WarrantMember 2026-09-30 0001844417 us-gaap:WarrantMember 2025-01-01 2025-12-31 0001844417 us-gaap:WarrantMember 2025-12-31 0001844417 us-gaap:WarrantMember 2024-01-01 2024-12-31 0001844417 us-gaap:WarrantMember 2024-12-31 0001844417 us-gaap:CommonStockMember 2026-09-30 0001844417 esla:PreFundedWarrantsMember 2026-09-30 0001844417 esla:CommonStockWarrantsMember 2026-09-30 0001844417 us-gaap:CommonStockMember esla:CommonStockWarrantsMember 2026-09-30 0001844417 us-gaap:CommonStockMember 2026-01-01 2026-09-30 0001844417 esla:PreFundedWarrantsMember 2026-01-01 2026-09-30 0001844417 esla:January2026RegisteredDirectOfferingAndPrivatePlacementMember 2026-01-05 2026-01-05 0001844417 2026-01-05 2026-01-05 0001844417 us-gaap:WarrantMember 2026-07-01 2026-09-30 0001844417 2026-09-28 2026-09-28 0001844417 2026-07-01 2026-07-01 0001844417 esla:SubscriptionAgreementsMember 2025-05-01 2025-09-30 0001844417 esla:TwoThousandTwentyFiveSecuritiesPurchaseAgreementsMember 2025-01-01 2025-12-31 0001844417 esla:InvestorsMember 2025-12-31 0001844417 esla:SecuritiesPurchaseAgreementsMember 2026-09-30 0001844417 esla:SubscriptionAgreementsMember us-gaap:CommonStockMember 2025-12-31 0001844417 esla:SubscriptionAgreementsMember us-gaap:CommonStockMember 2025-12-01 2025-12-31 0001844417 esla:PIPEInvestmentMember 2025-12-01 2025-12-31 0001844417 esla:PIPEInvestmentMember 2024-01-22 2024-01-22 0001844417 esla:SubscriptionAgreementsMember 2026-01-01 2026-09-30 0001844417 esla:PIPEInvestmentMember 2023-09-14 2023-09-14 0001844417 2025-12-31 0001844417 esla:EurekaMember 2025-01-01 2025-12-31 0001844417 esla:EurekaMember 2026-01-01 2026-09-30 0001844417 esla:SeriesAAPreferredStockMember 2022-06-28 0001844417 esla:CoFameMember 2025-01-01 2025-09-30 0001844417 esla:CoFameMember 2026-01-01 2026-09-30 0001844417 esla:CoFameMember 2025-07-01 2025-09-30 0001844417 esla:EurekaOneMember 2025-01-01 2025-09-30 0001844417 esla:EurekaOneMember 2026-01-01 2026-09-30 0001844417 esla:EurekaOneMember 2025-07-01 2025-09-30 0001844417 esla:EurekaOneMember 2026-07-01 2026-09-30 0001844417 esla:EurekaMember 2025-01-01 2025-09-30 0001844417 esla:EurekaMember 2026-01-01 2026-09-30 0001844417 esla:EurekaMember 2025-07-01 2025-09-30 0001844417 esla:EurekaMember 2026-07-01 2026-09-30 0001844417 esla:ConsultingAgreementMember 2026-01-01 2026-09-30 0001844417 esla:ConsultingAgreementMember us-gaap:RelatedPartyMember 2025-12-31 0001844417 us-gaap:RelatedPartyMember 2025-12-31 0001844417 us-gaap:RelatedPartyMember 2026-09-30 0001844417 esla:PatientTreatmentExpensesMember 2026-01-01 2026-09-30 0001844417 esla:SecondSiteActivationMember 2026-01-01 2026-09-30 0001844417 esla:PatientDosingMember 2026-01-01 2026-09-30 0001844417 esla:EurekaMember esla:StatementofWorkMember 2026-01-01 2026-09-30 0001844417 esla:EurekaMember 2026-09-30 0001844417 esla:EurekaMember 2023-10-10 2023-10-10 0001844417 2022-06-28 0001844417 2024-09-03 2024-09-03 0001844417 us-gaap:LicenseAgreementTermsMember 2026-01-01 2026-09-30 0001844417 us-gaap:FairValueMeasurementsRecurringMember 2026-07-01 2026-09-30 0001844417 us-gaap:FairValueMeasurementsRecurringMember 2026-06-30 0001844417 us-gaap:FairValueMeasurementsRecurringMember 2026-04-01 2026-06-30 0001844417 us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001844417 us-gaap:FairValueMeasurementsRecurringMember 2026-01-01 2026-03-31 0001844417 us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001844417 us-gaap:FairValueMeasurementsRecurringMember 2025-01-01 2025-12-31 0001844417 us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001844417 srt:MaximumMember 2025-01-01 2025-12-31 0001844417 srt:MinimumMember 2025-01-01 2025-12-31 0001844417 us-gaap:MeasurementInputSharePriceMember 2025-12-31 0001844417 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-01-01 2025-12-31 0001844417 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-01-01 2025-12-31 0001844417 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2025-01-01 2025-12-31 0001844417 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2025-01-01 2025-12-31 0001844417 us-gaap:FairValueInputsLevel3Member 2025-12-31 0001844417 esla:StandardInsuranceCoverageMember 2026-09-30 0001844417 esla:SecuritiesInvestorProtectionCorporationMember 2026-09-30 0001844417 esla:StockOptionsGrantedMember 2025-01-01 2025-09-30 0001844417 esla:StockOptionsGrantedMember 2025-07-01 2025-09-30 0001844417 esla:StockOptionsGrantedMember 2026-01-01 2026-09-30 0001844417 esla:StockOptionsGrantedMember 2026-07-01 2026-09-30 0001844417 esla:CommonStockWarrantMember 2026-01-01 2026-09-30 0001844417 esla:CommonStockWarrantMember 2026-07-01 2026-09-30 0001844417 us-gaap:WarrantMember 2025-01-01 2025-09-30 0001844417 us-gaap:WarrantMember 2025-07-01 2025-09-30 0001844417 us-gaap:WarrantMember 2026-01-01 2026-09-30 0001844417 us-gaap:WarrantMember 2026-07-01 2026-09-30 0001844417 esla:GoingConcernMember 2026-09-30 0001844417 us-gaap:PrivatePlacementMember 2026-01-06 2026-01-06 0001844417 2025-05-01 2025-09-30 0001844417 esla:SecuritiesPurchaseAgreementMember 2025-05-01 2025-09-30 0001844417 esla:GoingConcernMember 2026-01-01 2026-09-30 0001844417 2026-09-01 0001844417 2026-09-01 2026-09-01 0001844417 2026-08-17 0001844417 2026-08-17 2026-08-17 0001844417 2025-09-30 0001844417 2024-12-31 0001844417 us-gaap:RetainedEarningsMember 2026-09-30 0001844417 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001844417 us-gaap:TreasuryStockCommonMember 2026-09-30 0001844417 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001844417 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001844417 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001844417 2026-06-30 0001844417 us-gaap:RetainedEarningsMember 2026-06-30 0001844417 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001844417 us-gaap:TreasuryStockCommonMember 2026-06-30 0001844417 us-gaap:CommonStockMember 2026-06-30 0001844417 2026-04-01 2026-06-30 0001844417 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001844417 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001844417 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001844417 2026-03-31 0001844417 us-gaap:RetainedEarningsMember 2026-03-31 0001844417 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001844417 us-gaap:TreasuryStockCommonMember 2026-03-31 0001844417 us-gaap:CommonStockMember 2026-03-31 0001844417 2026-01-01 2026-03-31 0001844417 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001844417 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001844417 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001844417 us-gaap:RetainedEarningsMember 2025-12-31 0001844417 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001844417 us-gaap:TreasuryStockCommonMember 2025-12-31 0001844417 us-gaap:CommonStockMember 2025-12-31 0001844417 us-gaap:RetainedEarningsMember 2025-09-30 0001844417 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001844417 us-gaap:TreasuryStockCommonMember 2025-09-30 0001844417 us-gaap:CommonStockMember 2025-09-30 0001844417 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001844417 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001844417 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001844417 2025-06-30 0001844417 us-gaap:RetainedEarningsMember 2025-06-30 0001844417 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001844417 us-gaap:TreasuryStockCommonMember 2025-06-30 0001844417 us-gaap:CommonStockMember 2025-06-30 0001844417 2025-04-01 2025-06-30 0001844417 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001844417 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001844417 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001844417 2025-03-31 0001844417 us-gaap:RetainedEarningsMember 2025-03-31 0001844417 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001844417 us-gaap:TreasuryStockCommonMember 2025-03-31 0001844417 us-gaap:CommonStockMember 2025-03-31 0001844417 2025-01-01 2025-03-31 0001844417 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001844417 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0001844417 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001844417 us-gaap:RetainedEarningsMember 2024-12-31 0001844417 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001844417 us-gaap:TreasuryStockCommonMember 2024-12-31 0001844417 us-gaap:CommonStockMember 2024-12-31 0001844417 2026-11-11 0001844417 esla:WarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtAnExercisePriceOf1150Member 2026-01-01 2026-09-30 0001844417 esla:CommonStockParValue00001PerShareMember 2026-01-01 2026-09-30 0001844417 esla:CommonStockWarrantMember 2025-01-01 2025-09-30 0001844417 esla:PublicWarrantsMember 2026-09-30 0001844417 esla:PublicWarrantsMember 2025-12-31 0001844417 us-gaap:TreasuryStockCommonMember 2026-07-01 2026-09-30 0001844417 us-gaap:TreasuryStockCommonMember 2026-01-01 2026-03-31 0001844417 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001844417 us-gaap:TreasuryStockCommonMember 2026-04-01 2026-06-30 0001844417 esla:CommonStockWarrantMember 2025-07-01 2025-09-30 0001844417 us-gaap:FairValueInputsLevel1Member 2026-09-30 0001844417 us-gaap:FairValueInputsLevel2Member 2026-09-30 0001844417 us-gaap:FairValueInputsLevel3Member 2026-09-30 0001844417 us-gaap:FairValueInputsLevel1Member 2025-12-31 0001844417 us-gaap:FairValueInputsLevel2Member 2025-12-31 0001844417 us-gaap:FairValueMeasurementsRecurringMember 2026-09-30 0001844417 esla:CoFameMember 2026-07-01 2026-09-30 0001844417 esla:ConsultingAgreementMember us-gaap:RelatedPartyMember 2026-09-30 iso4217:USD xbrli:pure iso4217:USD xbrli:shares xbrli:shares esla:segment

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______________ to ______________

 

Commission File Number 001-40608

 

ESTRELLA IMMUNOPHARMA, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   86-1314502
(State or other jurisdiction of
incorporation or organization)
  (IRS Employer
Identification No.)

 

5858 Horton Street, Suite 370
Emeryville, California, 94608

(Address of principal executive offices and zip code)

 

(510) 318-9098 

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbols   Name of Each Exchange on Which Registered
Common Stock, par value $0.0001 per share   ESLA   The Nasdaq Stock Market LLC
Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50   ESLAW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
  Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

As of November 11, 2026, there were 43,970,085 shares of the issuer’s Common Stock, par value $0.0001 per share, outstanding.

 

 

 

 

 

 

ESTRELLA IMMUNOPHARMA, INC.

TABLE OF CONTENTS

 

      Page
Cautionary Note Regarding Forward-Looking Statements   ii
       
PART I. FINANCIAL INFORMATION   1
Item 1. Financial Statements   1
  Unaudited Condensed Consolidated Balance Sheets   1
  Unaudited Condensed Consolidated Statements of Operations   2
  Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Deficit   3
  Unaudited Condensed Consolidated Statements of Cash Flows   4
  Notes to Unaudited Condensed Consolidated Financial Statements   5
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations   26
Item 3. Quantitative and Qualitative Disclosures About Market Risk   36
Item 4. Controls and Procedures   36
       
PART II. OTHER INFORMATION   38
Item 1. Legal Proceedings   38
Item 1A. Risk Factors   38
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds   38
Item 3. Defaults Upon Senior Securities   38
Item 4. Mine Safety Disclosures   38
Item 5. Other Information   39
Item 6. Exhibits   39

 

i

 

 

Cautionary Note Regarding Forward-Looking Statements

 

This Quarterly Report on Form 10-Q (“Form 10-Q”) contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements are typically identified by words such as “plan,” “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “forecast,” “project,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “should,” “would” and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking.

 

The forward-looking statements are based on the current expectations of our management and are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date such statements are made. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those described in “Risk Factors” in Part II, Item 1A of this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K filed with the SEC on March 18, 2026.

 

These and other factors could cause actual results to differ from those implied by the forward-looking statements. Forward-looking statements are not guarantees of performance and speak only as of the date hereof. There can be no assurance that future developments will be those that have been anticipated or that we will achieve or realize these plans, intentions, or expectations.

 

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

 

In addition, statements of belief and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date they are made, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.

 

ii

 

 

PART I - FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS.

 

ESTRELLA IMMUNOPHARMA, INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

 

    As of
September 30,
2026
    As of
December 31,
2025
 
    (Unaudited)        
Assets            
Current Assets            
Cash and cash equivalents   $ 92,458     $ 1,384,302  
Prepaid expenses and other receivables     78,568       292,673  
Prepaid expenses, related party     1,500,000       -  
Total current assets     1,671,026       1,676,975  
                 
Other Assets                
Prepaid expenses, related party, non-current     -       1,500,000  
                 
Total Assets   $ 1,671,026     $ 3,176,975  
                 
Liabilities and Stockholders’ Deficit                
Current liabilities:                
Accounts payable - related party   $ 10,683     $ 554,781  
Other payables and accrued liabilities     308,970       238,414  
Accrued liability - related party     15,323,077       12,393,333  
Derivative liabilities     -       356,505  
Total current liabilities     15,642,730       13,543,033  
                 
Total Liabilities     15,642,730       13,543,033  
                 
Commitments and Contingencies (Note 4)                
                 
Preferred Stock                
Preferred Stock, $0.0001 par value, 10,000,000 shares authorized; 0 shares issued and outstanding as of September 30, 2026 and December 31, 2025     -       -  
                 
Stockholders’ Deficit:                
Common stock, $0.0001 par value; 250,000,000 shares authorized; 44,485,366 and 38,486,219 shares issued, and 43,970,085 and 37,970,938 shares outstanding as of September 30, 2026 and December 31, 2025, respectively     4,449       3,849  
Additional paid-in capital     35,593,524       27,219,287  
Accumulated deficit     (48,971,298 )     (36,990,815 )
Treasury stock, at cost 515,281 shares as of September 30, 2026 and December 31, 2025     (598,379 )     (598,379 )
Total Stockholders’ Deficit     (13,971,704 )     (10,366,058 )
Total Liabilities and Stockholders’ Deficit   $ 1,671,026     $ 3,176,975  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

1

 

 

ESTRELLA IMMUNOPHARMA, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

 

    For the
Three
Months
Ended
September 30,
2026
    For the
Three
Months
Ended
September 30,
2025
    For the
Nine
Months
Ended
September 30,
2026
    For the
Nine
Months
Ended
September 30,
2025
 
                         
Operating expenses                        
Research and development (includes related party expenses - see Note 5)   $ 6,900,396     $ 4,152,642     $ 9,700,903     $ 10,223,131  
General and administrative (includes related party expenses - see Note 5)     595,827       581,468       2,063,004       2,159,305  
Total operating expenses     7,496,223       4,734,110       11,763,907       12,382,436  
                                 
Loss from Operations     (7,496,223 )     (4,734,110 )     (11,763,907 )     (12,382,436 )
                                 
Other income (expenses):                                
Change in fair value of derivative liabilities     114,143       (67,039 )     (216,576 )     (67,039 )
Total other income (expenses)     114,143       (67,039 )     (216,576 )     (67,039 )
                                 
Loss before income tax     (7,382,080 )     (4,801,149 )     (11,980,483 )     (12,449,475 )
                                 
Income tax provision     -       -       -       (863 )
                                 
Net loss   $ (7,382,080 )   $ (4,801,149 )   $ (11,980,483 )   $ (12,450,338 )
                                 
Net loss applicable to common stock per share, basic and diluted   $ (0.17 )   $ (0.13 )   $ (0.28 )   $ (0.34 )
Weighted average common stock outstanding, basic and diluted     43,589,651       37,096,024       43,110,123       36,486,627  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.  

 

2

 

 

ESTRELLA IMMUNOPHARMA, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

 

                Additional           Total  
    Common Stock     Treasury     Paid-in     Accumulated     Stockholders’  
    Shares     Amount     Stock     Capital     Deficit     Equity (Deficit)  
Balance, December 31, 2024     36,680,870     $ 3,668     $ (568,917 )   $ 24,636,283     $ (23,927,303 )   $ 143,731  
Stock-based compensation     -       -       -       159,095       -       159,095  
Purchase of treasury stock     -       -       (29,462 )     -       -       (29,462 )
Net loss     -       -       -       -       (2,104,311 )     (2,104,311 )
Balance, March 31, 2025 (Unaudited)     36,680,870       3,668       (598,379 )     24,795,378       (26,031,614 )     (1,830,947 )
Stock-based compensation                             159,098               159,098  
Issuance of common stock for PIPE investment     900,000       90               1,121,969               1,122,059  
Net loss                                     (5,544,878 )     (5,544,878 )
Balance, June 30, 2025 (Unaudited)     37,580,870       3,758       (598,379 )     26,076,445       (31,576,492 )     (6,094,668 )
Stock-based compensation     -       -       -       152,421       -       152,421  
Issuance of common stock for PIPE investment     700,000       70       -       906,903       -       906,973  
Net loss     -       -       -       -       (4,801,149 )     (4,801,149 )
Balance, September 30, 2025 (Unaudited)     38,280,870     $ 3,828     $ (598,379 )   $ 27,135,769     $ (36,377,641 )   $ (9,836,423 )
                                                 
                                                 
Balance, December 31, 2025     38,486,219     $ 3,849     $ (598,379 )   $ 27,219,287     $ (36,990,815 )   $ (10,366,058 )
Stock-based compensation     -       -       -       146,714       -       146,714  
Issuance of common stock, prefunded warrants and common stock warrants for registered direct offering     4,063,290       406       -       7,240,700       -       7,241,106  
Exercise of prefunded warrants     631,000       63       -       (57 )     -       6  
Net loss     -       -       -       -       (2,292,064 )     (2,292,064 )
Balance, March 31, 2026 (Unaudited)     43,180,509       4,318       (598,379 )     34,606,644       (39,282,879 )     (5,270,296 )
Stock-based compensation     -       -       -       145,298       -       145,298  
Exercise of prefunded warrants     369,000       37       -       (33 )             4  
Net loss     -       -       -       -       (2,306,339 )     (2,306,339 )
Balance, June 30, 2026 (Unaudited)     43,549,509       4,355       (598,379 )     34,751,909       (41,589,218 )     (7,431,333 )
Stock-based compensation     -       -       -       105,628       -       105,628  
Issuance of common stock for settlement of true-up shares liability     735,857       74       -       573,007       -       573,081  
Exercise of stock options     200,000       20       -       162,980       -       163,000  
Net loss     -       -       -       -       (7,382,080 )     (7,382,080 )
Balance, September 30, 2026 (Unaudited)     44,485,366     $ 4,449     $ (598,379 )   $ 35,593,524     $ (48,971,298 )   $ (13,971,704 )

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

3

 

 

ESTRELLA IMMUNOPHARMA, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

 

    For the
Nine Months
Ended
September 30,
2026
    For the
Nine Months
Ended
September 30,
2025
 
Cash Flows from Operating Activities:            
Net loss   $ (11,980,483 )   $ (12,450,338 )
Adjustments to reconcile net loss to net cash used in operating activities:                
Stock-based compensation     397,640       470,614  
Change in fair value of derivative liabilities     216,576       67,039  
Changes in operating assets and liabilities:                
Prepaid expenses and other receivables     214,105       326,960  
Accounts payable - related party     (544,098 )     1,196  
Other payables and accrued liabilities     70,556       (126,145 )
Accrued liability - related party     2,929,744       10,106,666  
Franchise tax payable     -       (4,134 )
Income tax payable     -       (50 )
Net cash used in operating activities     (8,695,960 )     (1,608,192 )
                 
Cash Flows from Financing Activities:                
Payments of transactions costs     (758,882 )     (52,652 )
Proceeds received from issuance of common stock for PIPE investment     -       2,400,000  
Proceeds received from issuance of common stock, prefunded warrants and common stock warrants for registered direct offering     7,999,988       -  
Proceeds received from exercise of prefunded warrants     10       -  
Proceeds received from exercise of stock options     163,000       -  
Purchase of treasury stock     -       (29,462 )
Net cash provided by (used in) financing activities     7,404,116       2,317,886  
                 
Net Change in Cash and Cash Equivalents     (1,291,844 )     709,694  
                 
Cash and Cash Equivalents at beginning of the period     1,384,302       916,916  
Cash and Cash Equivalents at end of the period   $ 92,458     $ 1,626,610  
                 
Supplemental Cash Flow Information                
Cash paid for income tax   $ 1,600     $ 913  
Cash paid for interest   $ -     $ -  
                 
Supplemental Disclosure of Non-cash Financing Activities                
Recognition of derivative liabilities upon closing of the PIPE investment   $ -     $ 318,316  
Issuance of common stock for settlement of true-up shares liability   $ 573,081     $ -  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

4

 

 

Note 1 – Organization and Business Operations

 

Description of Business

 

Estrella Immunopharma, Inc. (“Estrella”), a Delaware corporation, is a clinical-stage biopharmaceutical company developing next-generation ARTEMIS® T-cell therapies for the treatment of cancer and autoimmune diseases.

 

Estrella was incorporated in the State of Delaware on March 30, 2022 by Eureka Therapeutics, Inc. (“Eureka”), which was incorporated in California in February 2006 and reincorporated in Delaware in March 2018 and is the predecessor of Estrella.

 

On June 28, 2022, pursuant to a Contribution Agreement between Estrella and Eureka (the “Contribution Agreement”), Eureka contributed certain assets (the “Assets”) related to T-cell therapies targeting CD19 and CD22, proteins expressed on the surface of almost all B-cell leukemias and lymphomas, in exchange for 105,000,000 shares of Estrella’s Series AA Preferred Stock (the “Separation”).

 

As part of the Separation, Estrella entered into a License Agreement (the “License Agreement”) with Eureka and Eureka Therapeutics (Cayman) Ltd. (“Eureka Cayman”), an affiliate of Eureka, and a Services Agreement (the “Services Agreement”) with Eureka, and Eureka contributed and assigned the Collaboration Agreement between Eureka and Imugene Limited (“Imugene”) (the “Collaboration Agreement”) to Estrella. The License Agreement grants the Company an exclusive license to develop CD19 and CD22 targeted T-cell therapies using Eureka’s ARTEMIS® platform. Under the Services Agreement, Eureka has agreed to perform certain services for the Company in connection with the development of the Company’s product candidates, EB103 and EB104. EB103, which is a T-cell therapy also called “CD19-Redirected ARTEMIS® T-Cell Therapy,” utilizes Eureka’s ARTEMIS® technology to target CD19. The Company is also developing EB104, a T-cell therapy also called “CD19/22 Dual-Targeting ARTEMIS® T-Cell Therapy.” Like EB103, EB104 utilizes Eureka’s ARTEMIS® technology to target not only CD19, but also CD22. The Collaboration Agreement establishes the partnership between the Company and Imugene related to development of solid tumor treatments using Imugene’s product candidate (“CF33-CD19t”) in conjunction with EB103.

 

On March 2, 2023, the FDA cleared Estrella’s IND application for EB103, allowing Estrella to proceed with the Phase I/II STARLIGHT-1 Clinical Trial (“STARLIGHT-1”). On March 4, 2024, the Company and Eureka executed Statement of Work No. 001 (“SOW”) relating to clinical trial services to be performed by Eureka in connection with the STARLIGHT-1 clinical trial. On May 13, 2024, the Company and Eureka entered into Amendment No. 1 to the Statement of Work, effective as of March 4, 2024 (see Note 5).

 

In November 2025, the Company announced the completion of Phase I dosing for the STARLIGHT-1 clinical trial. As of September 30, 2026, sixteen patients have been dosed in total, comprising nine patients in Phase I and seven patients in Phase II.

 

On September 29, 2023 (the “Closing Date”), Estrella and TradeUP Acquisition Corp. (“UPTD”) consummated the business combination (the “Business Combination”) under the terms of the Agreement and Plan of Merger, dated as of September 30, 2022 (the “Merger Agreement”), pursuant to which Estrella became a wholly-owned subsidiary of UPTD and UPTD changed its corporate name to Estrella Immunopharma, Inc. (the “Company”). The Business Combination was accounted for as a reverse recapitalization, with Estrella as the accounting acquirer, and the historical financial statements of Estrella became the historical financial statements of the Company.

 

On June 26, 2024, the Company completed a short-form merger to absorb its wholly-owned subsidiary, Estrella BioPharma Inc., and on November 25, 2024, our Board of Directors approved a change to our fiscal year end from June 30 to December 31.

 

5

 

 

In November 2024, the Company established Estrella Immunopharma (Hong Kong) Co. Ltd (“Estrella HK”) as a wholly-owned subsidiary in Hong Kong. This subsidiary was created to facilitate strategic collaborations and provide a local presence to support the Company’s operations and initiatives in Asia. As of September 30, 2026, Estrella HK had not commenced any operations.

 

On January 7, 2026, the Company received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5620(a) because it had not held an annual meeting of shareholders within twelve months of the end of its transition period ended December 31, 2024. On February 27, 2026, Nasdaq notified the Company that it has granted an extension until June 29, 2026 to regain compliance with this requirement. On June 29, 2026, the Company held its Combined 2025/2026 Annual Meeting of Stockholders, thereby regaining compliance with Nasdaq Listing Rule 5620(a).

 

On August 17, 2026, the Company received a notice from Nasdaq stating that, for the last 30 consecutive business days, the closing bid price of the Company’s Common Stock had been below the minimum of $1.00 per share required for continued listing under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until February 16, 2027, to regain compliance. If the Company does not regain compliance by that date, the Company may be eligible for an additional 180 calendar day compliance period.

 

On September 1, 2026, the Company received a notice from Nasdaq stating that, for the last 30 consecutive business days, the Company’s market value of listed securities had been below the minimum of $35.0 million required for continued listing under Nasdaq Listing Rule 5550(b)(2), and that the Company did not meet the alternative requirements under Nasdaq Listing Rules 5550(b)(1) or 5550(b)(3). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has a compliance period of 180 calendar days, or until March 1, 2027, to regain compliance. The notice has no immediate effect on the listing or trading of the Company’s Common Stock.

 

Going Concern

 

In assessing the Company’s liquidity and the substantial doubt about its ability to continue as a going concern, the Company monitors and analyzes cash on hand and operating expenditure commitments. The Company’s liquidity needs are to meet working capital requirements and operating expense obligations.

 

The Company’s management has considered whether there is substantial doubt about its ability to continue as a going concern based on the following factors: (1) recurring losses from operations of approximately $11.8 million for the nine months ended September 30, 2026; (2) an accumulated deficit of approximately $49.0 million as of September 30, 2026; (3) cash and cash equivalents of approximately $0.1 million as of September 30, 2026, compared with current liabilities of approximately $15.6 million, including approximately $15.1 million of accrued milestone obligations payable to Eureka and approximately $0.2 million of deferred salaries payable to the Company’s then Chief Executive Officer (now President and Chief Scientific Officer) and Chief Financial Officer; and (4) net cash used in operating activities of approximately $8.7 million for the nine months ended September 30, 2026. The Company has expended substantial funds on its research and development business, has experienced losses and negative cash flows from operations since its inception and expects losses and negative cash flows from operations to continue until its technology receives regulatory approval and the Company generates sufficient revenue and positive cash flow from operations, which may never occur. The Company’s ability to fund its operations is dependent on the amount of cash on hand and its ability to raise debt or additional equity financing, which may not be successful, available on acceptable terms, or available at all.

 

6

 

 

From May 2025 to September 2025, the Company entered into securities purchase agreements with certain investors, pursuant to which the Company issued 1,600,000 shares of common stock and received gross proceeds of approximately $2.4 million. Additionally, the Company consummated a registered direct offering and a concurrent private placement on January 6, 2026, resulting in gross proceeds of approximately $8.0 million. In addition, since the May 22, 2026 pay date, the Company’s then Chief Executive Officer (now President and Chief Scientific Officer) and its Chief Financial Officer have deferred payment of their base salaries, which totaled $198,077 as of September 30, 2026, and, effective October 25, 2026, the base salary of the Company’s new Chief Executive Officer is being deferred on the same terms. The deferred amounts do not bear interest and are payable in a lump sum after the earlier of a determination by the Board of Directors or its Compensation Committee that payment would not jeopardize the Company’s ability to continue as a going concern, which the Company anticipates making upon the closing of its next financing, and a change in control of the Company (see Notes 5 and 11). The Nasdaq deficiency notices described above may also adversely affect the Company’s ability to raise additional capital. As of September 30, 2026, the Company had not secured any additional financing, and management’s plans to obtain such financing are not considered probable of being effectively implemented under ASC 205-40. Despite these financing activities, the Company’s management is of the opinion that it will not have sufficient funds to meet the Company’s working capital requirements and debt obligations as they become due within one year from the issuance of these unaudited condensed consolidated financial statements due to the recurring loss. As a result, management has determined that there is substantial doubt about its ability to continue as a going concern. If the Company is unable to obtain adequate financing or generate significant revenue, it may be required to curtail or cease its operations.

 

Note 2 – Significant Accounting Policies

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X under the Securities Act. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.

 

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 18, 2026. The consolidated Balance Sheet as of December 31, 2025, was derived from the audited financial statements included in the Company’s Annual Report on Form 10-K. The interim results for the nine months ended September 30, 2026 are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2026 or for any future interim periods.

 

Principles of Consolidation

 

The unaudited condensed consolidated financial statements include the financial statements of the Company and its subsidiary. All transactions and balances among the Company and its subsidiary have been eliminated upon consolidation.

 

A subsidiary is an entity in which the Company, directly or indirectly, controls more than one half of the voting power; or has the power to govern the financial and operating policies, to appoint or remove the majority of the members of the board of directors, or to cast a majority of votes at the meeting of directors.

 

Emerging Growth Company Status

 

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

 

7

 

 

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies, but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s unaudited condensed consolidated financial statements with another public company difficult because of the potential differences in accounting standards used.

 

The Company became an emerging growth company upon the consummation of its initial public offering on July 19, 2021. Accordingly, the Company will remain an emerging growth company until the last day of the fiscal year in which the fifth anniversary of its initial public offering occurs, December 31, 2026, unless other criteria are met sooner.

 

Use of Estimates

 

The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods.

 

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. Significant items subject to such estimates and assumptions include stock-based compensation, the fair value of derivative liabilities, and deferred income tax asset valuation and allowances.

 

Cash and Cash Equivalents

 

The Company maintains its operating accounts in a single financial institution. The balance is insured by the United States Federal Deposit Insurance Corporation (“FDIC”) but only up to specified limits. The Company’s cash is maintained in a checking account. Cash equivalents consist of funds held in the third-party broker’s account for stock repurchase purposes; such funds are unrestricted and immediately available for withdrawal and use. The balance held at the third-party broker’s account is insured by the United States Securities Investor Protection Corporation (“SIPC”) but only up to specified limits.

 

Prepaid Expenses and Other Receivables

 

Prepaid expenses and other receivables primarily include prepayments for third-party services, such as professional fees, insurance premiums, and other items that will be recognized as expense in future periods as the related services are rendered.

 

8

 

 

Basic and Diluted Loss per Common Stock

 

Basic net loss per Common Stock is calculated by dividing the net loss by the weighted average number of shares of Common Stock outstanding during the period. In accordance with ASC 260, contingently issuable shares are included in the weighted average number of shares of Common Stock outstanding for basic net loss per share as of the date all necessary conditions for issuance have been satisfied and issuance of the shares is no longer contingent, regardless of whether the shares have been physically issued as of the reporting date.

 

Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of Common Stock and dilutive share equivalents outstanding for the period, determined using the treasury stock and if-converted methods, as applicable. Since the Company has incurred net losses for all periods presented, all potentially dilutive securities were anti-dilutive and therefore excluded from the computation of diluted net loss per share.

 

For the three and nine months ended September 30, 2026 and 2025, the Company had the following potential Common Stock outstanding which were not included in the calculation of diluted net loss per Common Stock because inclusion thereof would be anti-dilutive:

 

   

For the three and nine
months ended

September 30

 
    2026     2025  
    (Unaudited)     (Unaudited)  
Public warrant     2,214,993       2,214,993  
Common stock warrant     7,594,935       -  
Stock options outstanding     2,879,142       3,600,000  
Total     12,689,070       5,814,993  

 

Stock-Based Compensation

 

The Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an expense in the unaudited condensed consolidated statements of operations over the requisite service period based on a measurement of fair value for each stock-based award. The fair value of each option granted is estimated as of the date of grant using the Black-Scholes-Merton option-pricing model, net of actual forfeitures. The fair value is amortized as compensation cost on a straight-line basis over the requisite service period of the awards, which is generally the vesting period. The Black-Scholes-Merton option-pricing model includes various assumptions, including the fair market value of the Common Stock of the Company, expected life of stock options, the expected volatility and the expected risk-free interest rate, among others. These assumptions reflect the Company’s best estimates, but they involve inherent uncertainties based on market conditions generally outside the control of the Company.

 

As a result, if other assumptions had been used, stock-based compensation expense, as determined in accordance with authoritative guidance, could have been materially impacted. Furthermore, if the Company uses different assumptions on future grants, stock-based compensation expense could be materially affected in future periods.

 

9

 

 

Warrants

 

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own Common Stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

 

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. Based on the terms of the warrant agreements, the Company concluded that its warrants qualify for equity accounting treatment.

 

Upon completion of the business combination, all of UPTD’s public warrants that remained outstanding were replaced by the Company’s public warrants. The Company treated such warrant replacements as a warrant modification and no incremental fair value was recognized.

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentration of credit risk consist of one cash account in a financial institution located in the United States. The Company has not experienced losses on these accounts, and management believes the Company is not exposed to significant risks. The Federal Deposit Insurance Corporation (FDIC) provides standard insurance coverage of $250,000 per insured bank for each account ownership category. As of September 30, 2026, the Company had not experienced losses on these accounts. As of September 30, 2026 and December 31, 2025, the Company had deposited approximately $0.1 million and $1.4 million, respectively, with a financial institution in the United States. Of these balances, none and approximately $1.1 million, respectively, were not covered by deposit insurance. While management believes that the financial institution is of high credit quality, it also continually monitors its credit-worthiness.

 

The Securities Investor Protection Corporation (SIPC) provides standard insurance coverage of $500,000 per brokerage account, which includes $250,000 for cash balances. As of September 30, 2026 and December 31, 2025, the Company maintained approximately $500 in its brokerage account, with the entire balance covered by SIPC insurance.

 

Risks and Uncertainties

 

Management continues to evaluate the impact of inflation rates, the continuing military actions in Ukraine, Israel’s war against Hamas and the armed conflict between the U.S./Israel and Iran on the industry and has concluded that these factors could have a negative effect on the Company’s financial position and/or results of its operations. The specific impact of these factors is not readily determinable as of the date of these unaudited condensed consolidated financial statements. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

 

10

 

 

The Company’s future success depends on the Company and Eureka’s ability to retain key employees, directors, and advisors and to attract, retain and motivate qualified personnel. The Company relies on Eureka to provide certain technical assistance to facilitate the Company’s exploitation of the intellectual property licensed by Eureka, and Eureka will be solely responsible for the manufacture and supply of clinical quantities of the licensed products and final filled and finished (including packaged) drug product form of the licensed products. Pursuant to the Services Agreement, Eureka currently performs or supports the Company’s important research and development activities. The Statement of Work (see Note 5) may be terminated by mutual agreement at any time. Following the termination of, or the expiration of the term of, the Statement of Work, the Company may not be able to replace the research and development-related services that Eureka provides or enter into appropriate third-party arrangements on terms and conditions, including cost, comparable to those that the Company will receive from Eureka. Additionally, after the Statement of Work terminates, the Company may be unable to sustain the research and development-related services at the same levels or obtain the same benefits as when the Company was receiving such services and benefits from Eureka. If the Company is required to operate these research and development functions separately in the future, or is unable to obtain them from other providers, the Company may not be able to operate the Company’s business effectively, which could result in a material adverse effect.

 

Fair Value of Financial Instruments

 

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature. The Company measures the fair value of certain of its financial assets and liabilities on a recurring basis. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value which is not equivalent to cost will be classified and disclosed in one of the following three categories:

 

  Level 1 —  Quoted prices (unadjusted) in active markets for identical assets and liabilities.
     
  Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
     
  Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

The following table sets forth by level within the fair value hierarchy our financial asset and liability that were accounted for at fair value on a recurring basis as of September 30, 2026 and December 31, 2025:

 

    Carrying
Value at
September 30,
2026
    Fair Value Measurement at
September 30, 2026
 
    (Unaudited)     Level 1     Level 2     Level 3  
Derivative liabilities (True-Up Shares, Note 7)   $     -     $      -     $     -     $         -  

 

11

 

 

    Carrying
Value at
December 31,
    Fair Value Measurement at
December 31, 2025
 
    2025     Level 1     Level 2     Level 3  
Derivative liabilities (True-Up Shares, Note 7)   $ 356,505     $       -     $    -     $ 356,505  

 

The fair value of the derivative liability is a Level 3 measurement estimated using a Monte Carlo Simulation model.

 

During the three months ended September 30, 2026, the derivative liability associated with the additional shares of Common Stock issuable under the true-up provisions of the Securities Purchase Agreements entered into from May 2025 to September 2025 (the “True-Up Shares”) (see Note 7) was remeasured at fair value immediately prior to settlement. Upon issuance of the True-Up Shares, the related derivative liability with an aggregate fair value of $573,081 was settled and reclassified to common stock and additional paid-in capital.

 

As of December 31, 2025, the fair values of the derivative liabilities related to the True-Up Shares were valued at $356,505 using a Monte Carlo Simulation model. Key inputs included a volatility of 107% to 115%, a risk-free rate of 3.5% to 3.6%, and a spot price of $1.56 per share. The model captured the path-dependent payoff structure of the True-Up obligation and incorporated the terms of the contingent settlement feature, including the $0.99 to $1.08 True-Up Price and the Contractual Floor Price of $0.20 per share.

 

The following is a reconciliation of the beginning and ending balance of the financial liability measured at fair value on a recurring basis for the year ended December 31, 2025, and for the nine months ended September 30, 2026:

 

    Derivative
 Liabilities
 
Initial fair value of derivative liabilities attributable to True-Up Shares feature embedded in the Private Placement   $ 318,316  
Change in fair value of derivative liabilities     38,189  
Ending balance as of December 31, 2025     356,505  
Change in fair value of derivative liabilities     108,627  
Ending balance as of March 31, 2026     465,132  
Change in fair value of derivative liabilities     222,092  
Ending balance as of June 30, 2026     687,224  
Change in fair value of derivative liabilities     (114,143 )
Reclassification of derivative liabilities to equity upon issuance of True-Up Shares (Note 7)     (573,081 )
Ending balance as of September 30, 2026 (Unaudited)   $ -  

 

Derivative Liabilities

 

The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including the True-Up Shares in connection with the Securities Purchase Agreements entered into during May 2025 to September 2025 (refer to Note 7), to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and FASB ASC 815, Derivatives and Hedging (“ASC 815”). The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period.

 

The True-Up Shares embedded within Securities Purchase Agreement did not qualify as equity under ASC 815; therefore, the True-Up Shares are required to be bifurcated and classified as a liability and measured at fair value with subsequent changes in fair value recorded in the unaudited condensed consolidated statements of operations.

 

Income Tax

 

The Company recognizes deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards and establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.

 

12

 

 

Accounting for uncertainty in income taxes is recognized based on a recognition threshold and measurement process for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits and no amounts accrued for interest and penalties associated with unrecognized tax benefits as of September 30, 2026 and December 31, 2025. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company may be subject to potential examination by federal and state taxing authorities in the areas of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.

 

On July 4, 2025, the One Big Beautiful Bill Act (OBBBA) was signed into law in the U.S. The OBBBA includes changes to U.S. federal tax law, including extending and modifying certain key Tax Cuts and Jobs Act of 2017 provisions, and provisions allowing accelerated tax deductions for qualified property and research expenditures. The Company has completed its assessment and determined that the provisions did not have a material impact on its unaudited condensed consolidated financial statements.

 

The Company is incorporated in the State of Delaware and is required to pay franchise taxes to the State of Delaware on an annual basis.

 

Research and Development Expenses

 

The Company charges research and development costs to operations as incurred. The Company accrues costs incurred by related parties and external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed by third parties, patient enrollment in clinical trials when applicable, administrative costs incurred by third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expense in future periods as the related services are rendered. Research and development expenses for the three and nine months ended September 30, 2026 and 2025 primarily consisted of clinical trial costs incurred under the SOW. Refer to Note 5 for the terms of the License Agreement, the Services Agreement, and the Statement of Work.

 

Related Parties

 

Parties, which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence.

 

Lease

 

Effective July 1, 2022, the Company adopted ASU 2016-02, “Leases” (Topic 842), and elected the practical expedients that do not require the Company to reassess: (1) whether any expired or existing contracts are, or contain, leases, (2) lease classification for any expired or existing leases and (3) initial direct costs for any expired or existing leases. For lease terms of twelve months or fewer, a lessee is permitted to make an accounting policy election not to recognize lease assets and liabilities.

 

If any of the following criteria are met, the Company classifies the lease as a finance lease:

 

● The lease transfers ownership of the underlying asset to the lessee by the end of the lease term;

 

● The lease grants the lessee an option to purchase the underlying asset that the Company is reasonably certain to exercise;

 

13

 

 

● The lease term is for a major part of the remaining economic life of the underlying asset;

 

● The present value of the sum of the lease payments and any residual value guaranteed by the lessee, that is not otherwise included in the lease payments substantially exceeds all of the fair value of the underlying asset; or

 

● The underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term.

 

Leases that do not meet any of the above criteria are accounted for as operating leases.

 

The Company combines lease and non-lease components in its contracts under Topic 842, when permissible.

 

Operating lease right-of-use (“ROU”) asset and lease liability are recognized based on the present value of lease payments over the lease term. Since the implicit rate for the Company’s leases is not readily determinable, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that the Company would have to pay to borrow, on a collateralized basis, an amount equal to the lease payments, in a similar economic environment and over a similar term.

 

The Company reviews the impairment of its ROU asset consistent with the approach applied for its other long-lived assets when such assets are recognized. The Company reviews the recoverability of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on its ability to recover the carrying value of the asset from the expected undiscounted future pre-tax cash flows of the related operations. When operating ROU assets and lease liabilities are recognized, the Company includes the carrying amount of operating lease liability in any tested asset group and the associated operating lease payments in the undiscounted future pre-tax cash flows.

 

In the event of lease modification, the Company follows ASC 842-10-25 through 25-12, “lessee accounting for a modification that is not accounted for as a separate contract,” to remeasure and reallocate the remaining consideration in the lease agreement and reassess the classification of the lease at the effective date of the modification.

 

If, as a result of a lease modification or renewal, the remaining lease term is twelve months or less, the Company elects the short-term lease practical expedient and derecognizes any related operating lease ROU assets and lease liabilities. Following such derecognition, lease payments are recognized in profit or loss on a straight-line basis over the remaining lease term.

 

Segment Reporting

 

The chief executive officer is identified as the Company’s chief operating decision-maker (“CODM”). The CODM reviews financial information presented on a consolidated basis, including net income (loss), for purposes of allocating resources and evaluating financial performance. The Company has not generated revenue to date, and the CODM does not receive or review discrete financial information by business line, product, service or geographic area. Based on the management approach and the qualitative and quantitative criteria established by Accounting Standards Codification (“ASC”) 280, “Segment Reporting”, the Company considers itself to be operating within one operating and reportable segment.

 

Recent Accounting Pronouncements

 

The Company considers the applicability and impact of all accounting standards updates (“ASUs”). Management periodically reviews new accounting standards that are issued. Under the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), the Company meets the definition of an emerging growth company and has elected the extended transition period for complying with new or revised accounting standards, which delays the adoption of these accounting standards until they would apply to private companies. The Company will cease to qualify as an emerging growth company after December 31, 2026, and is assessing the effective dates of accounting standards that have not yet been adopted.

 

14

 

 

In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements, which amends U.S. GAAP to reflect updates and simplifications to certain disclosure requirements referred to FASB by the SEC. The targeted amendments incorporate 14 of the 27 disclosures referred by the SEC into Codification. Some of the amendments represent clarifications to, or technical corrections of, the current requirements. ASU 2023-06 could move certain disclosures from the nonfinancial portions of SEC filings to the financial statement notes. Each amendment in ASU 2023-06 will only become effective if the SEC removes the related disclosure or presentation requirement from its existing regulation by September 30, 2027. No amendments were effective as of September 30, 2026. The Company is still currently evaluating the impact of the adoption of the new standard but does not expect a significant impact on the consolidated financial statements.

 

On November 4, 2024, the FASB issued ASU No. 2024-03, Expense Disaggregation Disclosures (“ASU 2024-03”). ASU 2024-03 amends ASC 220, Comprehensive Income to expand income statement expense disclosures and require disclosure in the notes to the financial statements of specified information about certain costs and expenses. ASU 2024-03 is required to be adopted for fiscal years commencing after December 15, 2026, with early adoption permitted. The Company is currently evaluating the impact of adopting the standard on its financial position and results of operations.

 

The Company does not believe recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the Company’s unaudited condensed consolidated financial statements.

 

Note 3 – Other payables and accrued liabilities

 

Other payables and accrued liabilities consisted of the following:

 

    As of
September 30,
2026
    As of
December 31,
2025
 
    (Unaudited)        
Accrued professional fees (i)   $ 296,423     $ 162,162  
Salary and payroll taxes payable     9,688       57,501  
Others     2,859       18,751  
Total other payables and accrued liabilities   $ 308,970     $ 238,414  

 

(i) The balance of accrued professional fees represented amount due to third party service providers which include, legal and consulting fee related to research and development, and others.

 

Note 4 – Commitments and contingencies

 

Manufacturing Commitment

 

On June 28, 2022, Eureka and the Company entered into the License Agreement under which Eureka granted to the Company a license under certain intellectual property controlled by Eureka for exploitation by the Company in the Company’s territory under the License Agreement (the “Licensed Territory”). Estrella’s supply of clinical quantities of the licensed products and final filled and finished (including packaged) drug product form of the licensed products for development and commercialization purposes, both in the Licensed Territory and elsewhere, are to be manufactured either by Eureka, its affiliate or a third party contract manufacturer. Refer to Note 5.

 

15

 

 

Contingencies

 

From time to time, the Company is or may be party to certain legal proceedings, as well as certain asserted and un-asserted claims. Amounts accrued, as well as the total amount of reasonably possible losses with respect to such matters, individually and in the aggregate, are not deemed to be material to the Company’s unaudited condensed consolidated financial statements.

 

In some instances, the Company may be required to indemnify its licensors for the costs associated with any such adversarial proceedings or litigation. Third parties may assert infringement claims against the Company, its licensors, or its strategic collaborators based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation or other adversarial proceedings with the Company, its licensors, or its strategic collaborators to enforce or otherwise assert their patent rights.

 

Note 5 – Related party transactions

 

License Agreement

 

On June 28, 2022, in connection with the Contribution Agreement, Eureka Therapeutics, Inc. (“Eureka”), Eureka Therapeutics (Cayman) Ltd. (“Eureka Cayman”), and Estrella entered into a License Agreement under which Eureka and Eureka Cayman granted to Estrella a license under certain intellectual property controlled by Eureka for exploitation by Estrella in the Licensed Territory, which primarily includes the United States and the rest of the world, excluding China and the Association of Southeast Asian Nations (ASEAN) countries.

 

Pursuant to the License Agreement, during the term: (1) Eureka will manufacture and supply, either itself or through an affiliate or a third-party contract manufacturer, all of Estrella’s and its related parties’ clinical quantities requirements of the Licensed Products and final filled and finished (including packaged) drug product form of the Licensed Products (“Drug Product”) for development activities; and (2) Eureka will similarly supply all commercial quantities requirements of Drug Product for such development activities. Furthermore, Eureka and Estrella will form a Joint Steering Committee (“JSC”) to oversee the development and commercialization of the Licensed Products.

 

The License Agreement requires Estrella to make certain payments, including (a) an “upfront” payment of $1.0 million, payable in 12 equal monthly installments, (b) “milestone” payments upon the occurrence of certain events related to development and sales, with potential aggregate multi-million dollar payments upon FDA approval, and (c) royalty payments of a single-digit percentage on net sales.

 

As of September 30, 2026 and December 31, 2025, Estrella had no remaining balance of accounts payable - related party related to the upfront payment under the License Agreement. As of September 30, 2026, two development milestones Milestone 1 (IND submission of EB103 to the FDA) and Milestone 2 (first patient dosed in the first clinical trial of a licensed product) had been earned by Eureka under the Agreement. Milestone 1 was paid on October 10, 2023, and Milestone 2 ($50,000) was paid on September 3, 2024, both recorded as research and development expense in the Company’s unaudited condensed consolidated statements of operations.

 

16

 

 

Services Agreement

 

On June 28, 2022, Estrella entered into a Services Agreement with Eureka, as subsequently amended by Amendment No. 1 (effective October 1, 2022) and Amendment No. 2 (effective March 1, 2023). Pursuant to the Services Agreement, Eureka performs certain services for Estrella related to technology transfer and technical assistance to facilitate Estrella’s exploitation of the intellectual property licensed from Eureka. Under the Services Agreement, Estrella was to pay Eureka a non-refundable fee of $10.0 million in connection with the Services related to the Investigational New Drug (IND) application for EB103 and reimburses Eureka for reasonable pass-through costs. In addition, Estrella will be charged for other services performed by Eureka outside the scope of the Services per the Service Agreement, at a flat rate, by time or materials or as mutually agreed upon by the parties in writing.

 

Services provided by Eureka under the Services Agreement commenced in June 2022 and the IND application for EB103 allowance milestone was achieved in March 2023. Following the consummation of the Business Combination on September 29, 2023, the Company remitted approximately $9.3 million to Eureka on October 10, 2023. As of September 30, 2026 and December 31, 2025, the Company has settled all amounts owed under the Services Agreement, and there are no outstanding accounts payable or related-party liabilities associated with this agreement.

 

Statement of Work

 

On March 4, 2024, the Company and Eureka entered into Statement of Work No. 001 (“SOW”) relating to the clinical trial services to be performed by Eureka in connection with STARLIGHT-1, the Phase I/II clinical trial of the Company’s product candidate, EB103, a T-cell therapy targeting CD19 using Eureka’s ARTEMIS® T cell technology. The trial is designed to assess the safety, tolerability, recommended Phase II dose, and preliminary anti-cancer activity of EB103 for the treatment of relapsed or refractory (“R/R”) B-cell non-Hodgkin lymphoma (“NHL”) patients.

 

The SOW is governed by the terms of the Services Agreement (as amended) and incorporates all of its terms by reference. The scope of work includes study start-up, patient dosing and related activities, study close-out, and reporting, as well as regulatory document development, site activation, patient enrollment and consent management, data collection, and pharmacovigilance.

 

Pursuant to the SOW, Estrella agrees to pay Eureka non-refundable net fees in connection with the achievement of certain milestones set forth in the SOW, with total fees of $33.0 million for achievement of all milestones, excluding additional pass-through costs and expenses incurred by Eureka and payable by Estrella as further described below. Such amount assumes 20 patients to be dosed and one clinical site is activated. An additional $0.5 million would be payable to Eureka if a second site is activated following mutual agreement of Estrella and Eureka. In addition to the milestone payments, Eureka will invoice Estrella quarterly for additional pass-through costs and expenses incurred in connection with its services under the SOW. Pass-through cost details are summarized in the invoice, and supporting documents are provided upon Estrella’s request. Estrella is required to settle invoices within 30 days, with Eureka reserving the right to impose monthly interest charges of 1.5% for undisputed amounts unpaid after 30 days. Estrella will also be responsible for payment of any taxes, fees, duties or charges imposed by any governmental authority in connection with the services provided by Eureka under the SOW, other than any taxes on Eureka’s income.

 

The first invoice payable to Eureka issued upon execution of the SOW was $3.5 million, covering the fees associated with the initiation of the study, the preparation and activation of the first study site, and the First Patient First Visit (FPFV) milestones. Prior to the commencement of the patient dosing phase, a deposit of $1.5 million is required to be delivered to Eureka to ensure the readiness for patient treatment expenses and will be applied against the final invoice, and any unused portion will be returned to Estrella following collection of all outstanding fees and costs payable to Eureka under the SOW.

 

Additional invoices will be issued in connection with patient dosing milestones, amounting to approximately $1.4 million per patient and a total cost of $27.5 million for 20 patients, excluding any pass-through costs and additional expenses. Lastly, a $2.0 million milestone fee will become due in connection with the study close-out phase. Services provided in connection with this milestone include finalizing patient data, trial data cleaning, statistical analysis, and preparing and submitting the final study report.

 

17

 

 

As of September 30, 2026, the Company has paid $3.5 million to Eureka for fees associated with the study initiation milestones that have been achieved, $6.9 million for patient dosing, $0.5 million for second site activation, and deposited $1.5 million for patient treatment expenses, which will be applied to the final invoice, with any unused portion refunded once all fees are settled. The deposit of $1.5 million was recorded as prepaid expenses - related party on the unaudited condensed consolidated balance sheets.

 

As of September 30, 2026 and December 31, 2025, sixteen and nine patients had been dosed, respectively. The second clinical trial site was activated in April 2025, and three additional clinical trial sites were activated during the nine months ended September 30, 2026, for which no additional fees are payable under the SOW. During the nine months ended September 30, 2026, seven patients were dosed, and the Company recognized approximately $9.6 million of research and development expenses related to patient dosing milestones. All costs associated with patient dosing and second site activation were recorded as research and development expenses in the unaudited condensed consolidated statements of operations.

 

As of September 30, 2026, the Company accrued approximately $15.1 million under accrued liability – related party for outstanding dosing milestone payments due to Eureka. As of December 31, 2025, the Company accrued approximately $12.4 million under accrued liability – related party, and recorded $0.5 million as accounts payable – related party, which included amounts related to outstanding dosing milestone payments and second site activation costs.

 

On May 13, 2024, the Company and Eureka entered into Amendment No. 1 to the SOW, effective as of March 4, 2024, to clarify that in the event that Estrella exercises its right to terminate or suspend the engagement with Eureka by providing written notice to Eureka in accordance with the SOW, Estrella will only be obligated to compensate Eureka for (i) services provided by Eureka pursuant to the SOW (“Services”) in connection with milestones that were achieved prior to the date and time of such written notice, (ii) reasonable and documented pass-through costs incurred by Eureka on behalf of Estrella prior to the date and time of such written notice in connection with providing the Services and (iii) amounts payable to third parties pursuant to commitments reasonably entered into by Eureka on behalf of Estrella prior to the date and time of such written notice in connection with providing the Services, provided that Eureka shall make commercially reasonable efforts to cancel or reduce any such amounts.

 

Consulting Agreement

 

On November 1, 2024, the Company entered into a consulting agreement (the “Consulting Agreement”) with CoFame Investment Management Co. Ltd. (“CoFame Management”), a related party, as CoFame Management’s director, Hong Zhang, serves as a director of the Company. Pursuant to the Consulting Agreement, CoFame Management provides advisory and consulting services to the Company regarding activities in Asia, including investor relations and potential business collaborations, as mutually agreed from time to time. On June 29, 2026, the Company and CoFame Management mutually agreed to terminate the Consulting Agreement, effective July 1, 2026.

 

As of September 30, 2026, there were no outstanding amounts payable to CoFame Management. As of December 31, 2025, the Company had accrued $18,333 under accrued liability – related party and $36,666 under accounts payable – related party, representing unpaid consulting fees due to CoFame Management.

 

Deferred Officer Compensation

 

Beginning with the May 22, 2026 pay date, the Company deferred payment of the base salaries of its then Chief Executive Officer (now President and Chief Scientific Officer) and Chief Financial Officer to preserve cash. As of September 30, 2026, unpaid base salary of $198,077 owed to these officers was accrued and presented within accrued liability – related party on the unaudited condensed consolidated balance sheets. The Company had intended to resume payment upon the closing of a new financing, which has been delayed. The deferral is documented in Wage Deferral Agreements entered into on November 11, 2026 (see Note 11), under which the deferred amounts are fully earned and vested, do not bear interest, and are payable in a single lump sum within ten business days after the earlier of (i) a determination by the Board of Directors or its Compensation Committee that payment would not jeopardize the Company’s ability to continue as a going concern, which the Company anticipates making upon the closing of the financing transaction it is currently pursuing, and (ii) a change in control of the Company. The deferral continues for subsequent pay periods until the deferred amounts are paid; each officer may elect to end the deferral prospectively, and the Company may pay all or any portion of the deferred amounts at any time on a basis that treats the officers proportionately.

 

18

 

 

The following table summarizes research and development expenses and general and administrative expenses incurred by the Company in connection with related party transactions for the three and nine months ended September 30, 2026 and 2025, as discussed above.

 

Name of related party

  Relationship   Nature   For the
Three Months
Ended
September 30,
2026
    For the
Three Months
Ended
September 30,
2025
    For the
Nine Months
Ended
September 30,
2026
    For the
Nine Months
Ended
September 30,
2025
 
            (Unaudited)     (Unaudited)     (Unaudited)     (Unaudited)  
Eureka   Shareholders of the Company   Research and development expenses   $ 6,875,000     $ 4,125,000     $ 9,625,000     $ 10,125,000  
Eureka   Shareholders of the Company   General and administrative expenses     10,683       7,631       33,862       27,220  
CoFame Management   Hong Zhang, director of the Company, is a director of CoFame Management   General and administrative expenses     -       54,999       109,998       164,996  
Total           $ 6,885,683     $ 4,187,630     $ 9,768,860     $ 10,317,216  

 

Series AA Preferred Stock / Eureka Ownership

 

On June 28, 2022, Estrella and Eureka entered into the Contribution Agreement, pursuant to which Eureka agreed to contribute and assign to Estrella all rights, title and interest in and to the Assets in exchange for 105,000,000 shares of Estrella’s Series AA Preferred Stock. The issued shares of Series AA Preferred Stock were converted to Common Stock immediately prior to the closing of the Business Combination on September 29, 2023. As of September 30, 2026 and December 31, 2025, Eureka collectively owned approximately 57.5% and 66.6% of the Company’s outstanding shares, respectively. The decrease primarily reflects dilution from the January 2026 Registered Direct Offering and Private Placement (Note 7).

 

Lease

 

Refer to “Note 9 – Leases” 

 

Note 6 – Preferred stock

 

All previously issued shares of Series AA and Series A preferred stock were converted to common stock immediately prior to the closing of the business combination on September 29, 2023. Upon the closing of the business combination, the specific authorizations for Series AA and Series A preferred stock under the pre-merger certificate of incorporation were cancelled, and the Company’s Amended and Restated Certificate of Incorporation now authorizes 10,000,000 shares of undesignated preferred stock, par value $0.0001 per share. As of September 30, 2026 and December 31, 2025, no shares of preferred stock were issued or outstanding.

 

Note 7 – Stockholders’ deficit

 

The Company’s authorized shares of Common Stock is 250,000,000 with a par value of $0.0001 per share (the “Common Stock”). As of September 30, 2026 and December 31, 2025, there were 44,485,366 and 38,486,219 shares of Common Stock issued, respectively.

 

19

 

 

PIPE Investment Shares

 

In connection with the Merger, on September 14, 2023, UPTD entered into subscription agreements (the “Subscription Agreements”) with each of Plentiful Limited, a Samoan limited company (“Plentiful Limited”) and Lianhe World Limited (“Lianhe World,” together with Plentiful Limited, collectively, the “PIPE Investors”). Concurrently with the closing of the Business Combination, the Company issued 500,000 shares of Common Stock to each of Plentiful Limited and Lianhe World, respectively, for aggregate proceeds of $10,000,000.

 

Within thirty days following the date of the Closing, each PIPE Investor will also be entitled to receive 704,819 shares of Common Stock. Within five days following the date that is 24 months following the Closing (the “24-Month Date”), if the VWAP of Common Stock for the fifteen trading days prior to the 24-Month Date (the “24-Month Date VWAP”) is less than $8.30, then each of them will be entitled to a number of shares of Common Stock equal to (i) (A) 8.30 minus (B) the 24-Month Date VWAP multiplied by (ii) (A) the number of Shares held by the Investor on the 24-Month Date minus (B) the number of Shares acquired by the Investor following the Closing divided by 10.00. In accordance with the terms of the Subscription Agreements, the maximum number of shares to be issued at the 24-Month Date totals to 709,770.

 

On January 22, 2024, the Company completed the issuance of an additional 704,819 shares of Common Stock to each of the two PIPE Investors. The shares were issued as part of the consideration that each PIPE Investor was entitled to receive thirty days following the date of the closing of the Business Combination. In addition, in December 2025, the Company issued 205,349 additional shares to the PIPE Investors in accordance with the terms of the Subscription Agreements as the VWAP of the Company’s common stock for the fifteen (15) trading days prior to September 29, 2025 was less than $8.30, and based on the VWAP from September 8 to September 26, 2025.

 

Stock purchase agreement shares

 

- 2025 Securities Purchase Agreements

 

From May 2025 to September 2025, the Company entered into Securities Purchase Agreements with three accredited investors. Each Securities Purchase Agreement includes a contingent value protection feature pursuant to which the Company may be required to issue additional shares of Common Stock (the “True-Up Shares”) if the market price of the Company’s stock on the 12-month anniversary of each respective closing is below $1.50 per share. In 2025, the Company received gross proceeds of $2.4 million in connection with the executed Securities Purchase Agreements and issued 1,600,000 shares of its Common Stock to the investors, and incurred issuance costs of $117,473 related to the transaction. 

 

The True-Up feature was determined to require bifurcation from the host equity contract and is accounted for separately as a derivative liability under ASC 815. The derivative liability is initially measured at fair value on the issuance date and is remeasured at fair value at each subsequent reporting date, with changes in fair value recognized as other expenses in the unaudited condensed consolidated statements of operations. In accordance with the Securities Purchase Agreements executed between May 2025 to September 2025, the maximum number of True-Up Shares totals to 735,857.

 

On July 1, 2026 and September 28, 2026, the Company issued 463,636 and 272,221 True-Up Shares, respectively, representing the True-Up Shares issuable under the Securities Purchase Agreements. Upon satisfaction of the applicable conditions for issuance, the Company became unconditionally obligated to issue the respective True-Up Shares. Accordingly, pursuant to ASC 260-10-45-13, the True-Up Shares were included in the computation of basic net loss per share beginning on the respective dates the applicable contingencies were resolved. The related derivative liabilities were remeasured at fair value immediately prior to settlement, and the aggregate fair value of $573,081 was reclassified to common stock and additional paid-in capital upon issuance of the True-Up Shares. As of September 30, 2026, no further True-Up obligation remained outstanding.

 

Change in fair value recognized for the three and nine months ended September 30, 2026 were a gain of $114,143 and a loss of $216,576, respectively. Change in fair value recognized for the three and nine months ended September 30, 2025 were a loss of $67,039, which were previously reported within general and administrative expenses and have been reclassified to conform to the current period presentation.

 

20

 

 

- January 2026 Registered Direct Offering and Private Placement

 

On January 5, 2026, the Company entered into a Securities Purchase Agreement with a healthcare-focused institutional investor (the “January 2026 SPA”). On January 6, 2026, the Company consummated a registered direct offering (“RDO”) and a concurrent private placement pursuant to the January 2026 SPA, resulting in gross proceeds of approximately $8.0 million, before deducting placement agent fees and other offering expenses of approximately $0.8 million.

 

The Company issued 4,063,290 shares of common stock and pre-funded warrants (the “Pre-Funded Warrants”) to purchase 1,000,000 shares of common stock at an exercise price of $0.00001 per warrant share. The Company also issued common stock warrants (“Common Stock Warrants”) exercisable for up to 7,594,935 shares of Common Stock at an exercise price of $1.39 per warrant share, expiring on January 6, 2031.

 

Warrants

 

- Public Warrants

 

In connection with the reverse recapitalization, the Company has assumed 2,214,993 Public Warrants outstanding. Public Warrants met the criteria for equity classification.

 

Each whole Warrant entitles the registered holder to purchase one whole share of the Company’s Common Stock at a price of $11.50 per share. Pursuant to the warrant agreement, a warrant holder may exercise its Warrants only for a whole number of shares of Common Stock. This means that only a whole Warrant may be exercised at any given time by a warrant holder. No fractional Warrants will be issued upon separation of the Units and only whole Warrants will trade. The Warrants will expire at 5:00 p.m., New York City time, on September 29, 2028, which is five years after the completion of the Company’s initial Business Combination, or earlier upon redemption or liquidation.

 

The Company has agreed that as soon as practicable, but in no event later than 30 business days, after the closing of the initial Business Combination, it will use its commercially reasonable efforts to file, and within 60 business days following its initial Business Combination to have declared effective, a registration statement for the registration, under the Securities Act, of the shares of Common Stock issuable upon exercise of the Warrants.

 

The Company will use its commercially reasonable efforts to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the Warrants in accordance with the provisions of the warrant agreement. No Warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the Common Stock issuable upon exercise of the Warrants and a current prospectus relating to such shares of Common Stock. Notwithstanding the above, if the Company’s Common Stock is at the time of any exercise of a Warrant not listed on a national securities exchange such that it satisfies the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Warrants who exercise their Warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event it so elects, it will not be required to file or maintain in effect a registration statement, but it will be required to use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available.

 

21

 

 

Once the Warrants become exercisable, the Company may call the Warrants for redemption:

 

● in whole and not in part;

 

● at a price of $0.01 per Warrant;

 

● upon not less than 30 days’ prior written notice of redemption (the “30-day redemption period”) to each warrant holder; and

 

● if, and only if, the reported last sale price of the Common Stock equals or exceeds $16.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third business day before the Company sends the notice of redemption to the warrant holders.

 

The Company accounted for the 2,214,993 Public Warrants assumed from the merger as equity instruments in accordance with ASC 480, “Distinguishing Liabilities from Equity” and ASC 815-40, “Derivatives and Hedging: Contracts in Entity’s Own Equity”. As of September 30, 2026 and December 31, 2025, none of the Public Warrants had been exercised.

 

- Pre-Funded Warrants and Common Stock Warrants

 

In connection with the January 2026 SPA, the Company issued Pre-Funded Warrants to the investor to purchase 1,000,000 shares of common stock at an exercise price of $0.00001 per warrant share for a cash consideration of $1,579,990. In addition, the Company also issued common stock warrants (the “Common Stock Warrants”) exercisable for up to 7,594,935 shares of Common Stock at an exercise price of $1.39 per warrant share, expiring on January 6, 2031.

 

The Company accounted for the Pre-Funded Warrants and Common Stock Warrants as equity instruments in accordance with ASC 480, “Distinguishing Liabilities from Equity” and ASC 815-40, “Derivatives and Hedging: Contracts in Entity’s Own Equity”.

 

During the nine months ended September 30, 2026, 1,000,000 Pre-Funded Warrants were exercised, resulting in the issuance of 1,000,000 shares of Common Stock. As of September 30, 2026, no Pre-Funded Warrants remained unexercised.

 

As of September 30, 2026, none of the Common Stock Warrants had been exercised.

 

The summary of warrants activity is as follows:

 

    Warrants
outstanding
    Common stock issuable     Weighted
Average
Exercise
Price
    Average
Remaining
Contractual
Life
 
December 31, 2024     2,214,993       2,214,993     $ 11.5       3.67  
Granted     -       -       -       -  
Forfeited     -       -       -       -  
Exercised     -       -       -       -  
December 31, 2025     2,214,993       2,214,993     $ 11.5       2.67  
Granted     8,594,935       8,594,935       1.23       4.25  
Forfeited     -       -       -       -  
Exercised     (1,000,000 )     (1,000,000 )     0.00001       -  
September 30, 2026 (Unaudited)     9,809,928       9,809,928     $ 3.67       3.72  

 

22

 

 

Stock Repurchase Program

 

On January 30, 2024, the Company issued a press release announcing that its Board of Directors has authorized share repurchases of up to $1.0 million of its common stock. The authorization does not constitute a formal or binding commitment to make any share repurchases and the timing, amount and method of any share repurchases made pursuant to the authorization will be determined at a future date depending on market conditions and other factors.

 

During the nine months ended September 30, 2026, the Company did not repurchase any shares of its Common Stock in the open market. During the corresponding nine months ended September 30, 2025, the Company repurchased 28,302 shares of its Common Stock in open market transactions for an aggregate purchase price of $29,462, representing a weighted average price of $1.04 per share. As of September 30, 2026, and December 31, 2025, the Company has repurchased a cumulative total of 515,281 shares of its Common Stock, and approximately $0.4 million remained available for future repurchases under the authorization.

 

Note 8 – Stock-based compensation

 

At the special meeting of UPTD stockholders related to the Business Combination held on July 31, 2023, UPTD’s shareholders approved the adoption of the Company’s 2023 Omnibus Incentive Plan (the “2023 Plan”), which became effective on the Closing Date. Upon the closing of the Business Combination, 3,520,123 shares of common stock were authorized for issuance under the 2023 Plan.   The share reserve under the 2023 Plan increases automatically on January 1 of each year pursuant to an evergreen provision. Accordingly, the share reserve increased by 1,941,293 shares on January 1, 2024, by 1,920,444 shares on January 1, 2025, and by 2,115,684 shares on January 1, 2026. As of September 30, 2026, a total of 9,497,544 shares were authorized for issuance under the 2023 Plan, of which 6,418,402 shares remained available for future grant.

 

On October 30, 2024, the Company granted options under the 2023 Plan to purchase 3,600,000 shares of its Common Stock to its employees, board of directors, and other consultants. No additional stock options were granted during the nine months ended September 30, 2026 or the year ended December 31, 2025. In August 2026, the Company’s then Chief Executive Officer (now President and Chief Scientific Officer) and Chief Financial Officer each exercised 100,000 stock options at an exercise price of $0.815 per share, for aggregate cash proceeds of $163,000. In connection with the termination of the Consulting Agreement with CoFame Management effective July 1, 2026, 520,858 unvested stock options were forfeited, and no previously recognized compensation expense was reversed. The remaining 479,142 vested stock options held by CoFame Management were exercisable through October 1, 2026 (see Note 11).

 

The stock-based compensation expense was recorded in the Company’s results of operations. For the nine months ended September 30, 2026 and 2025, the stock-based compensation expense was $397,640 and $470,614, respectively.

 

The breakdown of stock-based compensation by categories for the three and nine months ended September 30, 2026 and 2025 is summarized below:

 

    For the
Three Months
Ended
September 30,
2026
    For the
Three Months
Ended
September 30,
2025
    For the
Nine Months
Ended
September 30,
2026
    For the
Nine Months
Ended
September 30,
2025
 
    (Unaudited)     (Unaudited)     (Unaudited)     (Unaudited)  
Research and development   $ 10,396     $ 10,414     $ 30,903     $ 30,903  
General and administrative     95,232       142,007       366,737       439,711  
Total stock-based compensation   $ 105,628     $ 152,421     $ 397,640     $ 470,614  

 

The aggregate grant date fair value of stock options granted under the 2023 Plan was $2,350,018, representing a weighted-average grant date fair value of $0.65 per share. As of September 30, 2026 and December 31, 2025, there were approximately $556,350 and $1,298,788 of unvested compensation costs, respectively, which are expected to be recognized over a weighted average remaining employment service period of approximately 1.45 and 2.29 years, respectively.

 

23

 

 

The Company estimated the fair value of the stock options using the Black-Scholes option pricing model. The fair value of stock options issued was estimated using the following assumptions:

 

    Assumptions
used for
October 30,
2024 grant
 
Exercise price   $ 0.815  
Stock price   $ 0.815  
Expected volatility     101.5-101.6 %
Expected term (in years)     5.5-6.0  
Risk-free interest rate     4.16-4.17 %
Expected dividend     0 %

 

The risk-free interest rate was obtained from U.S. Treasury rates for the applicable periods. The Company’s expected volatility was calculated from a blended volatility estimate from the implied volatility of a portfolio of comparable companies and the Company’s trading history since October 2, 2023. Due to a limited history of relevant stock option exercise activity, the expected life of the Company’s options was determined using the simplified method, which is based on the average of the time-to-vesting and the contractual life of the options.

 

A summary of information related to stock option activities for the nine months ended September 30, 2026 is as follows:

 

    Number of
Shares
    Weighted
Average
Exercise
Price Per
Share
    Weighted
Average
Remaining
Contractual
Term
    Aggregate
Intrinsic
Value
 
Options outstanding at December 31, 2025     3,600,000     $ 0.815       8.84     $ 2,682,000  
Granted     -       -                  
Exercised     (200,000 )     0.815                  
Forfeited     (520,858 )     0.815                  
Outstanding at September 30, 2026     2,879,142     $ 0.815       6.74     $ -  
Options vested and expected to vest at September 30, 2026     2,879,142     $ 0.815       6.74     $ -  
Options exercisable at September 30, 2026     2,024,972     $ 0.815       6.17     $ -  

 

Note 9 – Leases

 

The Company has entered into a series of short-term office sublease agreements with Eureka:

 

● Lease 3: January 1, 2025 to June 30, 2025, at $2,000 per month (six months)

 

● Lease 4: July 1, 2025 to December 31, 2025, at $2,000 per month (six months)

 

● Lease 5: January 1, 2026 to June 30, 2026, at $2,000 per month (six months)

 

● Lease 6: July 1, 2026 to December 31, 2026, at $2,000 per month (six months)

 

The Company’s office lease agreements do not contain any material residual value guarantees or material restrictive covenants. The agreements were classified as operating leases.

 

The Company elected not to apply the right-of-use asset and lease liability recognition requirements to the above short-term leases in accordance with ASC 842-20-25-2, as each lease term is less than twelve months. Accordingly, the Company continues to recognize the lease monthly payments in profit or loss on a straight-line basis over the remaining lease term period.

 

Rent expense for the three months ended September 30, 2026 and 2025 was $6,000. Rent expense for the nine months ended September 30, 2026 and 2025 was $18,000.

 

24

 

 

Note 10 – Segment Information

 

The Company conducts its business as a single operating and reportable segment based on its organizational and management structure and the manner in which the Chief Operating Decision Maker (“CODM”) reviews financial information to allocate resources and assess performance, consistent with the Company’s segment reporting policy described in Note 2. The accounting policies of the Company’s single operating segment are the same as those described in Note 2. The key measure of segment profitability used by the CODM to allocate resources and assess performance is net income (loss), as reported on the unaudited condensed consolidated statements of operations. The following table presents the significant expense categories of the Company’s single operating segment for the periods presented.

 

    For the Three Months Ended
September 30,
    For the Nine Months Ended
September 30,
 
    2026     2025     2026     2025  
    (Unaudited)     (Unaudited)     (Unaudited)     (Unaudited)  
Operating expenses and other expenses:                        
Clinical trial related service fee to related party (Note 5)   $ 6,875,000     $ 4,125,000     $ 9,625,000     $ 10,125,000  
Consulting fee     15,000       17,228       45,000       67,228  
Stock-based compensation (Note 8)     105,628       152,421       397,640       470,614  
Salary expense     132,820       132,054       392,856       392,861  
Professional fee     251,685       184,791       939,750       945,318  
Insurance expense     81,789       86,690       242,978       251,383  
Other general and administrative fee     34,301       35,926       120,683       130,032  
Change in fair value of derivative liabilities     (114,143 )     67,039       216,576       67,039  
Loss before income tax     7,382,080       4,801,149       11,980,483       12,449,475  
                                 
Income tax expense     -       -       -       863  
Net loss   $ 7,382,080     $ 4,801,149     $ 11,980,483     $ 12,450,338  

 

Note 11 – Subsequent Events

 

Expiration of Stock Options

 

On October 1, 2026, the 479,142 vested options held by CoFame Management expired unexercised (see Note 8).

 

Wage Deferral Agreements

 

On November 11, 2026, the Company entered into Wage Deferral Agreements with Cheng Liu, Ph.D., Jiandong (Peter) Xu and Cynthia Pussinen, which document the base salary deferral described in Note 5 and apply the same terms to Ms. Pussinen’s base salary for pay periods ending after October 25, 2026. The agreements were approved by the Compensation Committee and the Board of Directors.

 

Leadership Changes

 

Effective October 25, 2026, the Board of Directors increased the size of the Board to eight directors and appointed Cynthia Pussinen as Chief Executive Officer, Chairperson of the Board and a Class I director. Cheng Liu, Ph.D., who previously served as Chief Executive Officer, was appointed Chief Scientific Officer and continues to serve as President and as a director. In connection with her appointment, the Company entered into an employment agreement with Ms. Pussinen dated as of October 25, 2026, which provides for an annual base salary of $250,000, subject to automatic increases to $400,000, $450,000 and $525,000 when cumulative qualifying funding received by the Company after October 25, 2026 first exceeds $35.0 million, $55.0 million and $75.0 million, respectively; a target annual cash bonus of 60% of base salary for the fiscal year ending December 31, 2026; severance benefits upon certain qualifying terminations of employment; and the grant of an option to purchase 1,000,000 shares of Common Stock under the 2023 Plan. The option was granted on November 2, 2026 at an exercise price of $0.4263 per share, equal to the closing price of the Common Stock on the grant date, has a ten-year term and vests as to 25% of the shares on October 25, 2027 and as to the remainder in 36 substantially equal monthly installments thereafter, subject to continued service. On October 25, 2026, the Company also entered into amendments to the employment agreements of Dr. Liu and Mr. Xu that align their base salary, target annual cash bonus, benefits and severance terms with those provided to the Chief Executive Officer. The amendments do not provide for any new equity awards.

 

Milestones under Statement of Work #001

 

In October 2026, two additional patients were dosed in the STARLIGHT-1 clinical trial. The Company subsequently recorded an additional $2.75 million for these milestones under the SOW.

 

Except as described above, the Company did not identify any other subsequent events that would require recognition or disclosure in these unaudited condensed consolidated financial statements.

 

25

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company developing T-cell therapies with the capacity to potentially cure patients with blood cancers and solid tumors. Our operations have focused on the development and clinical testing of our lead product candidates, EB103 and EB104, and on the conduct of the STARLIGHT-1 Phase I/II clinical trial.

 

On March 2, 2023, the FDA cleared the IND application for EB103, allowing Estrella to proceed with the Phase I/II STARLIGHT-1 Clinical Trial. On March 4, 2024, Estrella and Eureka Therapeutics, Inc. (“Eureka”) entered into Statement of Work No. 001 (“SOW”) relating to the clinical trial services to be performed by Eureka in connection with STARLIGHT-1. Pursuant to the SOW, Estrella agrees to pay Eureka non-refundable net fees in connection with the achievement of certain milestones, with total fees of $33.5 million for achievement of all milestones, including a $0.5 million fee for the activation of the second clinical site. As of September 30, 2026, sixteen patients have been dosed in the STARLIGHT-1 clinical trial, and we accrued approximately $15.1 million in accrued liability - related party for the outstanding dosing milestone payments. As of September 30, 2026, Estrella has paid approximately $3.5 million to Eureka for fees associated with the study initiation milestones that have been achieved, approximately $6.9 million for patient dosing, and $0.5 million for second site activation.

 

To date, Estrella has funded its operations primarily from: (i) the June 28, 2022 issuance of $5.0 million of our Series A Preferred Stock; (ii) net proceeds of approximately $20.1 million raised from completion of the Business Combination on September 29, 2023; (iii) net proceeds of approximately $2.3 million from Securities Purchase Agreements entered into from May 2025 to September 2025; (iv) net proceeds of approximately $7.2 million from the Registered Direct Offering consummated on January 6, 2026; and (v) cash proceeds of $163,000 from the exercise of stock options in August 2026. We have a limited operating history. Since our inception, our operations have focused on preparing for the Business Combination, regulatory filings (including the INDs), planning preclinical and clinical studies, conducting the STARLIGHT-1 clinical trial, and building our management team. We do not have any product candidates approved for sale and have not generated any revenue from product sales.

 

As of September 30, 2026, we had an accumulated deficit of approximately $49.0 million. We have remitted payment of approximately $11.2 million to Eureka under the License Agreement and Services Agreement, paid approximately $10.9 million to Eureka for fees associated with milestones under SOW #001, and made a $1.5 million deposit for patient treatment expenses, which will be applied to the final invoice.

 

We anticipate that our expenses will increase significantly in connection with our ongoing activities, as we:

 

● continue to advance the STARLIGHT-1 clinical trial and preclinical programs;

 

● seek regulatory approval for any product candidates that successfully complete clinical trials;

 

● scale up our clinical and regulatory capabilities;

 

26

 

 

● adapt our regulatory compliance efforts to incorporate requirements applicable to marketed products;

 

● maintain, expand, and protect our intellectual property portfolio;

 

● add operational, financial, and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts; and

 

● incur additional legal, accounting, and other expenses in operating as a public company.

 

Recent Developments

 

STARLIGHT-1 Clinical Trial Progress

 

In November 2025, the Company announced the completion of Phase I dosing in the STARLIGHT-1 clinical trial of EB103, our lead product candidate. In 2026, seven Phase II patients have been dosed in the STARLIGHT-1 clinical trial, two during the six months ended June 30, 2026 and five during the three months ended September 30, 2026. All dosing milestones recognized as of September 30, 2026 have been recorded as research and development expense under the SOW with Eureka. During the nine months ended September 30, 2026, three additional clinical trial sites were activated, for which no additional fees are payable under the SOW. The Company continues to enroll patients and advance the STARLIGHT-1 clinical trial.

 

January 2026 Registered Direct Offering and Private Placement

 

On January 6, 2026, the Company consummated a Registered Direct Offering (“RDO”) and concurrent Private Placement pursuant to a Securities Purchase Agreement entered into with a healthcare-focused institutional investor, resulting in gross proceeds of approximately $8.0 million before deducting placement agent fees and other offering expenses of approximately $0.8 million.

 

The Company issued 4,063,290 shares of Common Stock and Pre-Funded Warrants to purchase 1,000,000 shares of Common Stock at an exercise price of $0.00001 per warrant share pursuant to its shelf registration statement. The Company also issued Common Stock Warrants exercisable for up to 7,594,935 shares of Common Stock at an exercise price of $1.39 per warrant share, expiring on January 6, 2031. On January 16, 2026, the Company filed Amendment No. 1 to its registration statement on Form S-1 to add the resale of shares issuable upon exercise of the Common Stock Warrants. The registration statement became effective on January 23, 2026.

 

During the nine months ended September 30, 2026, 1,000,000 Pre-Funded Warrants were exercised, resulting in the issuance of 1,000,000 shares of Common Stock. As of September 30, 2026, no Pre-Funded Warrants remained unexercised.

 

Issuance of True-Up Shares

 

On July 1, 2026 and September 28, 2026, the Company issued 463,636 and 272,221 True-Up Shares, respectively, under the Securities Purchase Agreements entered into from May 2025 to September 2025, representing all True-Up Shares issuable under those agreements. The related derivative liabilities, with an aggregate fair value of $573,081, were reclassified to common stock and additional paid-in capital upon issuance, and no further True-Up obligation remained outstanding as of September 30, 2026.

 

Deferred Officer Compensation

 

Beginning with the May 22, 2026 pay date, we deferred payment of the base salaries of our then Chief Executive Officer, Cheng Liu, Ph.D., and our Chief Financial Officer, Jiandong (Peter) Xu, to preserve cash. As of September 30, 2026, unpaid base salary of $198,077 was accrued and presented within accrued liability – related party on our unaudited condensed consolidated balance sheet. We had intended to resume payment upon the closing of a new financing, which has been delayed. On November 11, 2026, we entered into Wage Deferral Agreements with Dr. Liu, Mr. Xu and our new Chief Executive Officer, Cynthia Pussinen, whose base salary is being deferred on the same terms for pay periods ending after October 25, 2026. Under the Wage Deferral Agreements, the deferred amounts are fully earned and vested, do not bear interest, and are payable in a single lump sum within ten business days after the earlier of (i) a determination by our Board of Directors or its Compensation Committee that payment would not jeopardize our ability to continue as a going concern, which we anticipate making upon the closing of the financing transaction we are currently pursuing, and (ii) a change in control. The deferral continues for subsequent pay periods until the deferred amounts are paid; each officer may elect to end the deferral prospectively, and we may pay all or any portion of the deferred amounts at any time on a proportionate basis. The Wage Deferral Agreements were approved by the Compensation Committee and our Board of Directors.

 

Leadership Changes

 

Effective October 25, 2026, our Board of Directors increased the size of the Board to eight directors and appointed Cynthia Pussinen as our Chief Executive Officer, Chairperson of the Board and a Class I director. Dr. Liu, who previously served as our Chief Executive Officer, was appointed Chief Scientific Officer and continues to serve as our President and as a director. In connection with her appointment, we entered into an employment agreement with Ms. Pussinen dated as of October 25, 2026, and granted her an option to purchase 1,000,000 shares of Common Stock under the 2023 Plan. On October 25, 2026, we also entered into amendments to the employment agreements of Dr. Liu and Mr. Xu that align their base salary, target annual cash bonus, benefits and severance terms with those provided to our Chief Executive Officer. See Note 11 to our unaudited condensed consolidated financial statements for a description of the material terms of these arrangements. Also on October 25, 2026, our Board of Directors adopted resolutions providing that the Board will not exercise its authority under our certificate of incorporation to leave any class of directors unoccupied, and approved, and directed that there be submitted to our stockholders for approval at our 2027 annual meeting of stockholders, an amendment to our certificate of incorporation that would remove that authority and provide that the classes of directors be as nearly equal in number as possible.

 

27

 

 

Board Change and Termination of CoFame Consulting Agreement

 

On June 29, 2026, the Company and CoFame Management (of which Hong Zhang is a director) mutually agreed to terminate the Consulting Agreement effective July 1, 2026. Additionally, on July 7, 2026, Hong Zhang resigned as Chairperson of the Board of Directors and continues to serve as a director. In connection with the termination of the Consulting Agreement with CoFame Management effective July 1, 2026, 520,858 unvested stock options were forfeited, and the remaining 479,142 vested stock options held by CoFame Management were exercisable through October 1, 2026. As of September 30, 2026, there were no outstanding amounts payable to CoFame Management.

 

Stock Option Exercises

 

In August 2026, the Company’s then Chief Executive Officer (now President and Chief Scientific Officer) and Chief Financial Officer each exercised 100,000 stock options at an exercise price of $0.815 per share, for aggregate cash proceeds of $163,000.

 

Business Combination and Corporate History

 

On September 29, 2023, we consummated the Business Combination with TradeUP Acquisition Corp. (“UPTD”) pursuant to the terms of the Merger Agreement. For financial accounting and reporting purposes under GAAP, Estrella was the accounting acquirer, and the Business Combination was accounted for as a reverse recapitalization. The consolidated assets, liabilities, and results of operations of Estrella became the historical consolidated financial statements of the combined company.

 

On June 26, 2024, the Company completed a short-form merger to absorb its wholly-owned subsidiary, Estrella BioPharma Inc., and on November 25, 2024, our Board of Directors approved a change to our fiscal year end from June 30 to December 31. On November 27, 2024, the Company established Estrella Immunopharma (Hong Kong) Co. Ltd. (“Estrella HK”) as a wholly-owned subsidiary to support strategic collaborations and operations in Asia. As of September 30, 2026, Estrella HK had not commenced any operations.

 

Nasdaq Listing Compliance

 

On January 7, 2026, we received a written notice from Nasdaq indicating that we were not in compliance with Nasdaq Listing Rule 5620(a) due to our failure to hold an annual meeting of shareholders within twelve months of the end of our transition period ended December 31, 2024. On February 27, 2026, Nasdaq granted us an extension until June 29, 2026 to regain compliance. The Company held its Combined 2025/2026 Annual Meeting of Stockholders on June 29, 2026, thereby regaining compliance with Nasdaq Listing Rule 5620(a).

 

On August 17, 2026, we received a notice from Nasdaq stating that, for the last 30 consecutive business days, the closing bid price of our Common Stock had been below the minimum of $1.00 per share required for continued listing under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have a compliance period of 180 calendar days, or until February 16, 2027, to regain compliance. If we do not regain compliance by that date, we may be eligible for an additional 180 calendar day compliance period.

 

On September 1, 2026, we received a notice from Nasdaq stating that, for the last 30 consecutive business days, our market value of listed securities had been below the minimum of $35.0 million required for continued listing under Nasdaq Listing Rule 5550(b)(2), and that we did not meet the alternative requirements under Nasdaq Listing Rules 5550(b)(1) or 5550(b)(3). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), we have a compliance period of 180 calendar days, or until March 1, 2027, to regain compliance. The notice has no immediate effect on the listing or trading of our Common Stock.

 

28

 

 

Results of Operations

 

Estrella was formed on March 30, 2022, and has not commenced revenue-producing operations. To date, our operations have consisted of the development and clinical-stage testing of our product candidates, EB103 and EB104, preparation and submission of the IND application for EB103, and conduct of the STARLIGHT-1 clinical trial.

 

Results of Operations for the Three Months Ended September 30, 2026 and 2025 (Unaudited)

 

Research and Development Expenses

 

Research and development expenses consist primarily of costs related to conducting work related to the STARLIGHT-1 clinical trial, which is principally performed by Eureka under the SOW.

 

For the three months ended September 30, 2026 and 2025, we incurred approximately $6.9 million and $4.2 million of research and development expenses, respectively. The increase of approximately $2.7 million, or 66.2%, was primarily attributable to five patients dosed under SOW #001 during the three months ended September 30, 2026, compared with three patients dosed during the three months ended September 30, 2025. All research and development expenses incurred for the periods presented were dedicated to the development of ARTEMIS® T-cell therapies targeting CD19 and CD22.

 

The breakdown of research and development expenses by category for the three months ended September 30, 2026 and 2025 is summarized below:

 

    For the
three months
ended
September 30,
2026
    For the
three months
ended
September 30,
2025
 
    (Unaudited)     (Unaudited)  
Clinical trial related service fee to related party (Note 5)   $ 6,875,000     $ 4,125,000  
Consulting fee     15,000       17,228  
Stock-based compensation     10,396       10,414  
Total research and development   $ 6,900,396     $ 4,152,642  

 

General and Administrative Expenses

 

For the three months ended September 30, 2026 and 2025, general and administrative expenses were approximately $0.6 million and $0.6 million, respectively, representing an increase of approximately $14,000, or 2.5%. The increase was primarily attributable to higher professional fees, partially offset by lower stock-based compensation and other general and administrative expenses.

 

29

 

 

Change in Fair Value of Derivative Liabilities

 

For the three months ended September 30, 2026 and 2025, the Company recognized a gain of approximately $0.1 million and a loss of approximately $67,000, respectively, from the change in fair value of derivative liabilities. The 2025 loss was previously reported within general and administrative expenses and has been reclassified to conform to the current period presentation. The 2026 gain was primarily attributable to the remeasurement of the derivative liabilities associated with the True-Up feature embedded in the Securities Purchase Agreements entered into between May and September 2025, immediately prior to their settlement upon the issuance of the True-Up Shares on July 1, 2026 and September 28, 2026.

 

Net Loss

 

We incurred a net loss of approximately $7.4 million and $4.8 million for the three months ended September 30, 2026 and 2025, respectively. We expect our research and development expenses to continue to increase as we continue to work with Eureka to advance the IND filings, preclinical and clinical development of our product candidates and preclinical programs, seek regulatory approval for any product candidates that successfully complete clinical trials, scale up our clinical and regulatory capabilities, adapt our regulatory compliance efforts to incorporate requirements applicable to marketed products, maintain, expand, and protect our intellectual property portfolio, add operational, financial, and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts, and incur additional legal, accounting, and other expenses in operating as a public company.

 

Results of Operations for the Nine Months Ended September 30, 2026 and 2025 (Unaudited)

 

Research and Development Expenses

 

Research and development expenses consist primarily of costs related to conducting work related to the STARLIGHT-1 clinical trial, which is principally performed by Eureka under the SOW.

 

For the nine months ended September 30, 2026 and 2025, we incurred approximately $9.7 million and $10.2 million of research and development expenses, respectively. The decrease of approximately $0.5 million, or 5.1%, was primarily attributable to the second clinical site activation milestone recognized under SOW #001 during the nine months ended September 30, 2025, with no corresponding site activation fee during the nine months ended September 30, 2026, as seven patients were dosed in each period. All research and development expenses incurred for the periods presented were dedicated to the development of ARTEMIS® T-cell therapies targeting CD19 and CD22.

 

The breakdown of research and development expenses by category for the nine months ended September 30, 2026 and 2025 is summarized below:

 

    For the
nine months
ended
September 30,
2026
    For the
nine months
ended
September 30,
2025
 
    (Unaudited)     (Unaudited)  
Clinical trial related service fee to related party (Note 5)   $ 9,625,000     $ 10,125,000  
Consulting fee     45,000       67,228  
Stock-based compensation     30,903       30,903  
Total research and development   $ 9,700,903     $ 10,223,131  

 

30

 

 

Research and development expenses for the nine months ended September 30, 2026 included costs associated with seven patients dosed under SOW #001, compared with costs associated with one site activation and seven patients dosed in the nine months ended September 30, 2025. Stock-based compensation allocated to research and development remained consistent at approximately $10,000 per quarter for both periods.

 

General and Administrative Expenses

 

For the nine months ended September 30, 2026 and 2025, general and administrative expenses were approximately $2.1 million and $2.2 million, respectively, representing a decrease of approximately $0.1 million, or 4.5%. The decrease was primarily attributable to lower stock-based compensation and other general and administrative expenses.

 

Change in fair value of derivative liabilities

 

For the nine months ended September 30, 2026, the Company recognized a loss of approximately $0.2 million from the change in fair value of derivative liabilities, compared to a loss of approximately $67,000 for the nine months ended September 30, 2025, which was previously reported within general and administrative expenses and has been reclassified to conform to the current period presentation. The 2026 loss was primarily attributable to the remeasurement of the derivative liabilities associated with the True-Up feature embedded in the Securities Purchase Agreements entered into between May and September 2025, including their final remeasurement immediately prior to their settlement upon the issuance of the True-Up Shares on July 1, 2026 and September 28, 2026.

 

Net Loss

 

We incurred a net loss of approximately $12.0 million and $12.5 million for the nine months ended September 30, 2026 and 2025, respectively. We expect our research and development expenses to continue to increase as we continue to work with Eureka to advance the IND filings, preclinical and clinical development of our product candidates and preclinical programs, seek regulatory approval for any product candidates that successfully complete clinical trials, scale up our clinical and regulatory capabilities, adapt our regulatory compliance efforts to incorporate requirements applicable to marketed products, maintain, expand, and protect our intellectual property portfolio, add operational, financial, and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts, and incur additional legal, accounting, and other expenses in operating as a public company.

 

Liquidity and Capital Resources

 

As of September 30, 2026, we had cash and cash equivalents of approximately $0.1 million and a working capital deficit of approximately $14.0 million, with current liabilities of approximately $15.6 million, including approximately $15.1 million of accrued milestone obligations payable to Eureka and approximately $0.2 million of deferred base salary payable to our executive officers. Since our inception, we have expended substantial funds on research and development and have experienced significant losses and negative cash flows from operations. For the nine months ended September 30, 2026, we reported a net loss of approximately $12.0 million and net cash used in operating activities of approximately $8.7 million. As of September 30, 2026, we had an accumulated deficit of approximately $49.0 million.

 

Going Concern and Management’s Assessment of Liquidity

 

We expect our expenses and operating losses to increase significantly as we continue to advance our product candidates through clinical development, particularly in connection with the Phase I/II STARLIGHT-1 clinical trial of EB103. Our recurring losses from operations, accumulated deficit, and need for additional financing to fund future operations, raise substantial doubt about our ability to continue as a going concern.

 

31

 

 

To fund our operations, we completed a private placement between May and September 2025, receiving gross proceeds of approximately $2.4 million. On January 6, 2026, we consummated a registered direct offering and concurrent private placement resulting in gross proceeds of approximately $8.0 million. In addition, since the May 22, 2026 pay date, our then Chief Executive Officer (now President and Chief Scientific Officer) and our Chief Financial Officer have deferred payment of their base salaries, which totaled $198,077 as of September 30, 2026, and the base salary of our new Chief Executive Officer is being deferred on the same terms effective October 25, 2026. The deferred amounts do not bear interest, and we intend to pay them in a lump sum as soon as our Board of Directors or its Compensation Committee determines that payment would not jeopardize our ability to continue as a going concern, which we anticipate upon the closing of our next financing, or upon a change in control, if earlier. See “Recent Developments—Deferred Officer Compensation.” As of September 30, 2026, we had not secured any additional financing, and management’s plans to obtain such financing are not considered probable of being effectively implemented under ASC 205-40. The Nasdaq deficiency notices described above may also adversely affect our ability to raise additional capital. Despite these recent financing activities, management is of the opinion that we will not have sufficient funds to meet our working capital requirements and debt obligations as they become due within one year from the date of this report. If we are unable to obtain adequate financing or generate significant revenue, we may be required to curtail or cease our operations.

 

Material Cash Requirements and Capital Sources

 

Our primary use of cash is to fund operating expenses, primarily consisting of clinical trial activities and related research and development costs. Pursuant to the SOW with Eureka for the STARLIGHT-1 clinical trial, we agreed to pay total non-refundable net fees of $33.5 million for the achievement of all projected milestones, including a $0.5 million fee for the activation of the second clinical site. As of September 30, 2026, we have cumulatively incurred approximately $26.0 million to Eureka for milestones achieved, and we hold an accrued liability to related parties of approximately $15.1 million for the outstanding milestone payments.

 

Our ability to fund our operations is dependent on our cash on hand, our ability to raise debt or additional equity financing, and ultimately our ability to generate sufficient revenue. We plan to raise additional capital in the future; however, there is no assurance that such financing will be available on acceptable terms, or at all. Furthermore, while we have tradeable warrants outstanding, it is unlikely that holders will exercise these warrants to provide additional liquidity in the near term, as the current market price of our Common Stock ($0.7939 per share as of November 11, 2026) is significantly lower than the $11.50 per share exercise price. Additionally, our Common Stock Purchase Agreement with White Lion Capital LLC expired on December 30, 2025, and is no longer available as a source of liquidity.

 

Cash Flows

 

Operating Activities

 

Net cash used in operating activities was approximately $8.7 million for the nine months ended September 30, 2026, and was primarily attributable to (a) a net loss of approximately $12.0 million and (b) a decrease of approximately $0.5 million in accounts payable – related party, primarily due to the payment of the second site activation fee previously due to Eureka, offset by (i) approximately $0.6 million (net) non-cash items, consisting of change in fair value of derivative liabilities and stock-based compensation under the 2023 Plan, (ii) an increase of approximately $2.9 million in accrued liability – related party, primarily due to additional patient dosing milestones incurred from Eureka and approximately $0.2 million of deferred officer compensation, (iii) an increase of approximately $71,000 in other payables and accrued liabilities, and (iv) a decrease of approximately $0.2 million in prepaid expenses and other receivables primarily due to the utilization of previously recorded prepaid expenses during the nine months ended September 30, 2026.  

 

Net cash used in operating activities was approximately $1.6 million for the nine months ended September 30, 2025, and was primarily attributable to (a) a net loss of approximately $12.5 million, and (b) approximately $0.1 million decrease in other payables and accrued liabilities primarily due to the settlement of various previously accrued expenses, offset by (i) approximately $10.1 million increase in accrued liability – related party as additional service charges were incurred from Eureka following the completion of seven patients dosing and a site activation milestone (see Note 5 and Commitments and Contingencies section), (ii) approximately $0.5 million increase in non-cash item of stock-based compensation under the 2023 Plan and an approximately $67,000 loss from the change in fair value of derivative liabilities, and (iii) approximately $0.3 million decrease in prepaid expenses and other receivables primarily due to the utilization of previously recorded prepaid expenses during the nine months ended September 30, 2025.

 

32

 

 

Financing Activities

 

Net cash provided by financing activities was approximately $7.4 million for the nine months ended September 30, 2026, and was primarily attributable to net proceeds of approximately $7.2 million received from the Registered Direct Offering and concurrent Private Placement consummated on January 6, 2026, net of placement agent fees and offering expenses, and $163,000 of cash proceeds from the exercise of stock options by our then Chief Executive Officer (now President and Chief Scientific Officer) and Chief Financial Officer in August 2026.

 

Net cash provided by financing activities was approximately $2.3 million for the nine months ended September 30, 2025, consisting of approximately $2.4 million of gross proceeds from the issuance of common stock in a private placement, partially offset by approximately $53,000 of transaction costs and approximately $29,000 of open market repurchases of our common stock under our stock repurchase program.

 

Off-Balance Sheet Arrangements

 

As of September 30, 2026 and December 31, 2025, we did not have, nor do we currently have, any off-balance sheet arrangements as defined under the rules and regulations of the SEC.

 

Commitments and Contingencies

 

In the normal course of business, we are subject to loss contingencies, such as legal proceedings and claims arising out of our business, that cover a wide range of matters, including, among others, government investigations and tax matters. In accordance with ASC 450-20, “Loss Contingencies,” we will record accruals for such loss contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated.

 

License Agreement

 

Pursuant to the License Agreement with Eureka, we were obligated to make, and may be required to make as applicable: (i) a one-time, non-refundable, non-creditable payment of $1.0 million, payable in twelve equal monthly installments; (ii) certain one-time, non-refundable, non-creditable development “milestone” payments upon the occurrence of certain events related to development and sales, with potential aggregate multi-million dollar payments upon FDA approval; and (iii) royalty payments of a single-digit percentage on net sales.

 

As of September 30, 2026, we have fully paid the $1.0 million license fee to Eureka. Two development milestones - the IND submission of EB103 to the FDA (“Milestone 1”, $50,000, paid October 2023) and the first patient dosed in the first clinical trial of a licensed product (“Milestone 2”, $50,000, paid September 2024) have been earned by Eureka and paid in full. No other development milestones, sales milestones, or royalty payments have been earned or are payable, as we do not have any product candidates approved for sale and have not generated any revenue from product sales.

 

Services Agreement

 

Pursuant to the Services Agreement, we agreed to pay Eureka $10.0 million in connection with the services thereunder, payable in twelve equal monthly installments, and to reimburse Eureka on a monthly basis for reasonable pass-through costs. In addition, we will be charged for other services performed by Eureka outside the scope of the services set forth in the Services Agreement, at a flat rate, by time or materials or as mutually agreed upon by the parties in writing. As of September 30, 2026, we have fully settled all amounts owed under the Services Agreement, and there are no outstanding accounts payable or related-party liabilities associated with this agreement.

 

Statement of Work

 

Pursuant to the SOW (and Amendment No. 1), Estrella agreed to pay Eureka total fees of up to $33.5 million in connection with the Phase I/II clinical trial of EB103, including a $0.5 million fee for the activation of the second clinical site. As of September 30, 2026, sixteen patients have been dosed and five clinical sites have been activated.

 

33

 

 

Amounts related to the SOW are accrued as earned by Eureka and recorded as research and development expense. As of September 30, 2026, approximately $15.1 million in earned but not yet formally invoiced milestone payments were recorded as accrued liability - related party on our unaudited condensed consolidated balance sheet. The $1.5 million deposit for patient treatment expenses continues to be recorded as prepaid expenses - related party, current, and will be applied against the final invoice.

 

Office Lease

 

Effective July 1, 2026, the Company entered into a successor short-term office sublease with Eureka for the period from July 1, 2026 through December 31, 2026, at a monthly fee of $2,000. Rent expense was $6,000 for each of the three months ended September 30, 2026 and 2025, and $18,000 for each of the nine months ended September 30, 2026 and 2025.

 

Equity Financing — 2025 Securities Purchase Agreements

 

From May 2025 to September 2025, we entered into Securities Purchase Agreements with three accredited investors. Each agreement includes a True-Up feature pursuant to which we may be required to issue additional shares of Common Stock (up to a maximum of 735,857 True-Up Shares in aggregate) if our Common Stock price is below $1.50 on the 12-month anniversary of each respective closing. This True-Up feature was recorded as a derivative liability, measured at fair value through earnings. On July 1, 2026 and September 28, 2026, we issued 463,636 and 272,221 True-Up Shares, respectively, representing all True-Up Shares issuable under the Securities Purchase Agreements. The related derivative liabilities were remeasured at fair value immediately prior to settlement, and the aggregate fair value of $573,081 was reclassified to common stock and additional paid-in capital. As of September 30, 2026, no further True-Up obligation remained outstanding.

 

Equity Financing — January 2026 Registered Direct Offering

 

In connection with the January 6, 2026 RDO, we issued Common Stock Warrants exercisable for up to 7,594,935 shares of Common Stock at $1.39 per share, expiring January 6, 2031. The Common Stock Warrants are equity-classified. We also fulfilled our registration obligation related to the Common Stock Warrants through a Form S-1 that became effective January 23, 2026. As of September 30, 2026, no Common Stock Warrants have been exercised.

 

Critical Accounting Policies and Estimates

 

Our financial statements and accompanying notes have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses, and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.

 

We have identified certain accounting estimates that are significant to the preparation of our financial statements. These estimates are important for an understanding of our financial condition and results of operations. Certain accounting estimates are particularly sensitive because of their significance to our financial statements and because of the possibility that future events affecting the estimate may differ significantly from management’s current judgments. We believe no critical accounting estimate was identified other than the following significant estimates and accounting policies.

 

34

 

 

Derivative Liabilities

 

We evaluate all of our financial instruments, including the True-Up Shares in connection with the Securities Purchase Agreement, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and FASB ASC 815, Derivatives and Hedging (“ASC 815”). The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period.

 

During the nine months ended September 30, 2026, the derivative liabilities associated with the True-Up Shares were remeasured at fair value at each reporting period, and immediately prior to their settlement on July 1, 2026 and September 28, 2026. Upon issuance of the True-Up Shares, the related derivative liability with an aggregate fair value of $573,081 was settled and reclassified to common stock and additional paid-in capital. As of September 30, 2026, no derivative liability remained outstanding. As of December 31, 2025, the fair value of the derivative liability related to the True-Up Shares was valued at $356,505 using a Monte Carlo Simulation model. Key inputs included a volatility of 107% to 115%, a risk-free rate of 3.5% to 3.6%, and a spot price of $1.56 per share. The model captured the path-dependent payoff structure of the True-Up obligation and incorporated the terms of the contingent settlement feature, including the $0.99 to $1.08 True-Up Price and the Contractual Floor Price of $0.20 per share.

 

Stock-Based Compensation

 

We recognize compensation costs resulting from the issuance of stock-based awards to employees, non-employees, and directors as an expense in the unaudited condensed consolidated statements of operations over the requisite service period based on a measurement of fair value for each stock-based award. The fair value of each option granted is estimated as of the date of grant using the Black-Scholes-Merton option-pricing model, net of actual forfeitures. The fair value is amortized as compensation cost on a straight-line basis over the requisite service period of the awards, which is generally the vesting period. The Black-Scholes-Merton option-pricing model includes various assumptions, including the fair market value of Estrella Common Stock, expected life of stock options, the expected volatility, and the expected risk-free interest rate, among others. These assumptions reflect our best estimates, but they involve inherent uncertainties based on market conditions generally outside of our control.

 

As a result, if other assumptions had been used, stock-based compensation expense, as determined in accordance with authoritative guidance, could have been materially impacted. Furthermore, if we use different assumptions on future grants, stock-based compensation expense could be materially affected in future periods.

 

We account for the fair value of equity instruments issued to non-employees using either the fair value of the services received or the fair value of the equity instrument, whichever is considered more reliable. We utilize the Black-Scholes-Merton option-pricing model to measure the fair value of options issued to non-employees.

 

We record compensation expense for the awards with graded vesting using the straight-line method. We recognize compensation expense over the requisite service period applicable to each individual award, which generally equals the vesting term. Forfeitures are recognized when realized. For the nine months ended September 30, 2026 and 2025, stock-based compensation expense was $397,640 and $470,614, respectively. As of September 30, 2026, unrecognized compensation cost related to unvested stock options was approximately $556,350, which is expected to be recognized over a weighted average period of approximately 1.45 years.

 

Emerging Growth Company and Smaller Reporting Company Status

 

As an emerging growth company, we have elected to use the extended transition period for complying with new or revised accounting standards as permitted by the JOBS Act, which allows us to delay the adoption of these standards until they apply to private companies. We will cease to qualify as an emerging growth company after December 31, 2026.

 

35

 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Our disclosure controls and procedures are designed to ensure that the information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission (“SEC”) rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

 

As required by Rules 13a-15 and 15d-15 under the Exchange Act, our management, with the participation and supervision of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this quarterly report. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of such date, our disclosure controls and procedures were not, in design and operation, effective as of September 30, 2026 at a reasonable assurance level due to the material weakness in internal control over financial reporting described below:

 

Material Weaknesses

 

A material weakness is a deficiency, or a combination of deficiencies, within the meaning of Public Company Accounting Oversight Board Auditing Standard AS 2201, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. We had the following material weakness:

 

● We did not have qualified full-time personnel with appropriate levels of accounting knowledge and experience to address complex GAAP accounting issues and to prepare and review financial statements and related disclosures under GAAP.

 

36

 

 

In light of this material weakness, we performed additional analysis as deemed necessary to ensure that our financial statements were prepared in accordance with GAAP. Accordingly, management believes that the financial statements included in this Quarterly Report on Form 10-Q present fairly in all material respects our financial position, results of operations and cash flows for the period presented.

 

Changes in Internal Control over Financial Reporting

 

The Company has implemented certain changes in its internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) to remediate the material weaknesses identified in fiscal year ended December 31, 2025 and the six-month transition period ended December 31, 2024. The implementation of the material aspects of this plan took place during 2025 and 2024. The remediation efforts included:

 

● Additional qualified personnel with appropriate levels of accounting knowledge and experience to address GAAP accounting issues have been engaged to prepare and review financial statements and related disclosures under GAAP.

 

● Implementing processes whereby non-routine transactions are analyzed by in-house staff and third-party consultants to ensure proper accounting treatment.

 

● Establishing narratives and policies for business processes that relate to financial statements have been put in place to establish proper segregation of duties and internal controls.

 

There were no changes in our internal control over financial reporting that occurred during the three months ended September 30, 2026, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Our Chief Executive Officer and Chief Financial Officer concluded that as of September 30, 2026, our disclosure controls and procedures were not effective at the reasonable assurance level.

 

Limitations on Effectiveness of Controls and Procedures

 

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

 

37

 

 

PART II - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

None.

 

ITEM 1A. RISK FACTORS

 

Factors that could cause our actual results to differ materially from those included in this Quarterly Report are any of the risks described under “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on March 18, 2026. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. Except as set forth below, as of the date of this Quarterly Report, there have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K filed with the SEC on March 18, 2026. 

 

Our Common Stock and Warrants may be delisted from Nasdaq if we do not regain compliance with Nasdaq’s minimum bid price and minimum market value of listed securities requirements.

 

On August 17, 2026, we received a notice from Nasdaq that the closing bid price of our Common Stock had been below the $1.00 minimum bid price required for continued listing under Nasdaq Listing Rule 5550(a)(2) for 30 consecutive business days, and on September 1, 2026, we received a notice from Nasdaq that the market value of our listed securities had been below the $35.0 million minimum required under Nasdaq Listing Rule 5550(b)(2) for 30 consecutive business days and that we did not meet the alternative stockholders’ equity or net income requirements. We have until February 16, 2027 and March 1, 2027, respectively, to regain compliance with these requirements. We may not be able to regain compliance within the applicable periods, and any additional compliance period we may be granted for the bid price deficiency is not available for the market value deficiency. We may seek stockholder approval of a reverse stock split of our Common Stock in order to regain compliance with the minimum bid price requirement, which would not by itself cure the market value deficiency and could reduce the liquidity of our Common Stock. If our Common Stock is delisted from Nasdaq, our Warrants would also be delisted, and our securities would likely trade on an over-the-counter market, which could reduce their liquidity and market price, subject them to the “penny stock” rules, limit the interest of institutional investors and impair our ability to raise capital. If our Common Stock is not listed on a national securities exchange, we will be permitted to require holders of our public warrants to exercise them on a cashless basis.

 

We have deferred payment of the base salaries of our executive officers and have substantial accrued obligations to Eureka, our controlling stockholder, and our ability to continue our operations depends on obtaining additional financing in the near term.

 

As of September 30, 2026, we had cash and cash equivalents of approximately $0.1 million and current liabilities of approximately $15.6 million, including approximately $15.1 million of accrued clinical trial milestone payments owed to Eureka under the SOW and $198,077 of deferred base salary owed to our executive officers. Since the May 22, 2026 pay date we have deferred payment of the base salaries of our executive officers, including the base salary of our new Chief Executive Officer, beginning with pay periods ending after October 25, 2026, and the deferred amounts will continue to accrue until we obtain financing sufficient to pay them without jeopardizing our ability to continue as a going concern. Our executive officers are not obligated to continue to defer their salaries, and continued deferral may adversely affect our ability to retain them. Eureka, our controlling stockholder, is not obligated to continue to defer collection of the amounts we owe it or to continue to provide services under the SOW if we are unable to pay. We have not secured any additional financing, our ability to raise capital may be adversely affected by the Nasdaq deficiency notices described above, and management has concluded that there is substantial doubt about our ability to continue as a going concern. If we are unable to obtain adequate financing in the near term, we may be required to delay, reduce or terminate the STARLIGHT-1 clinical trial, curtail or cease our operations, or seek protection under applicable bankruptcy laws, and our stockholders could lose all or part of their investment.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

38

 

 

ITEM 5. OTHER INFORMATION

 

During the quarter ended September 30, 2026, no director or officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.

 

ITEM 6. EXHIBITS

 

The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

 

Exhibit
Number
  Description of Exhibit
31.1*   Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*   Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**   Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**   Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS   Inline XBRL Instance Document
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.SCH   Inline XBRL Taxonomy Extension Schema Document
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   Inline XBRL Taxonomy Extension Labels Linkbase Document
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

* Filed herewith.
   
** These certifications are furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

 

39

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  ESTRELLA IMMUNOPHARMA, INC.
     
  By: /s/ Cynthia Pussinen
  Name: Cynthia Pussinen
  Title: Chief Executive Officer (Principal Executive Officer)
     
  Date: November 13, 2026

 

  By: /s/ Peter Xu
  Name: Peter Xu
  Title: Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)
     
  Date: November 13, 2026

 

40

 

Keep reading